<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83976</article-id><article-id pub-id-type="doi">10.7554/eLife.83976</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Nucleotide binding is the critical regulator of ABCG2 conformational transitions</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-296261"><name><surname>Gyöngy</surname><given-names>Zsuzsanna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296262"><name><surname>Mocsár</surname><given-names>Gábor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296263"><name><surname>Hegedűs</surname><given-names>Éva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-122905"><name><surname>Stockner</surname><given-names>Thomas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7071-8283</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296264"><name><surname>Ritter</surname><given-names>Zsuzsanna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296265"><name><surname>Homolya</surname><given-names>László</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296266"><name><surname>Schamberger</surname><given-names>Anita</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-296267"><name><surname>Orbán</surname><given-names>Tamás I</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-296268"><name><surname>Remenyik</surname><given-names>Judit</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-124654"><name><surname>Szakacs</surname><given-names>Gergely</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9311-7827</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-294833"><name><surname>Goda</surname><given-names>Katalin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2001-7400</contrib-id><email>goda@med.unideb.hu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02xf66n48</institution-id><institution>Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen</institution></institution-wrap><addr-line><named-content content-type="city">Debrecen</named-content></addr-line><country>Hungary</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02xf66n48</institution-id><institution>Doctoral School of Molecular Cell and Immune Biology, University of Debrecen</institution></institution-wrap><addr-line><named-content content-type="city">Debrecen</named-content></addr-line><country>Hungary</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05n3x4p02</institution-id><institution>Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03zwxja46</institution-id><institution>Institute of Enzymology, Research Centre for Natural Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Budapest</named-content></addr-line><country>Hungary</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02xf66n48</institution-id><institution>Institute of Food Technology, Faculty of Agricultural and Food Sciences and Environmental Management, University of Debrecen</institution></institution-wrap><addr-line><named-content content-type="city">Debrecen</named-content></addr-line><country>Hungary</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03prydq77</institution-id><institution>Institute of Cancer Research, Medical University of Vienna</institution></institution-wrap><addr-line><named-content content-type="city">Vienna</named-content></addr-line><country>Austria</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>02</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83976</elocation-id><history><date date-type="received" iso-8601-date="2022-10-05"><day>05</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-27"><day>27</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-10-21"><day>21</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.19.512890"/></event></pub-history><permissions><copyright-statement>© 2023, Gyöngy et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Gyöngy et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83976-v1.pdf"/><abstract><p>ABCG2 is an exporter-type ABC protein that can expel numerous chemically unrelated xeno- and endobiotics from cells. When expressed in tumor cells or tumor stem cells, ABCG2 confers multidrug resistance, contributing to the failure of chemotherapy. Molecular details orchestrating substrate translocation and ATP hydrolysis remain elusive. Here, we present methods to concomitantly investigate substrate and nucleotide binding by ABCG2 in cells. Using the conformation-sensitive antibody 5D3, we show that the switch from the inward-facing (IF) to the outward-facing (OF) conformation of ABCG2 is induced by nucleotide binding. IF-OF transition is facilitated by substrates, and hindered by the inhibitor Ko143. Direct measurements of 5D3 and substrate binding to ABCG2 indicate that the high-to-low affinity switch of the drug binding site coincides with the transition from the IF to the OF conformation. Low substrate binding persists in the post-hydrolysis state, supporting that dissociation of the ATP hydrolysis products is required to reset the high substrate affinity IF conformation of ABCG2.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>ABCG2</kwd><kwd>catalytic cycle</kwd><kwd>conformation changes</kwd><kwd>substrate binding</kwd><kwd>confocal microscopy</kwd><kwd>fluorescence correlation spectroscopy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018818</institution-id><institution>National Research, Development and Innovation Office</institution></institution-wrap></funding-source><award-id>K124815</award-id><principal-award-recipient><name><surname>Goda</surname><given-names>Katalin</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018818</institution-id><institution>National Research, Development and Innovation Office</institution></institution-wrap></funding-source><award-id>HunProtEx 2018-1.2.1-NKP-2018-00005</award-id><principal-award-recipient><name><surname>Szakacs</surname><given-names>Gergely</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100018818</institution-id><institution>National Research, Development and Innovation Office</institution></institution-wrap></funding-source><award-id>RRF-2.3.1-21-2022-00015</award-id><principal-award-recipient><name><surname>Szakacs</surname><given-names>Gergely</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>SFB35</award-id><principal-award-recipient><name><surname>Szakacs</surname><given-names>Gergely</given-names></name><name><surname>Stockner</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008530</institution-id><institution>European Regional Development Fund</institution></institution-wrap></funding-source><award-id>GINOP-2.2.1-15-2017-00079</award-id><principal-award-recipient><name><surname>Remenyik</surname><given-names>Judit</given-names></name><name><surname>Goda</surname><given-names>Katalin</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The conformational switch of ABCG2 from the high substrate affinity inward-facing to a low substrate affinity outward-facing state is induced by nucleotide binding and accelerated by transported substrates.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The human ABCG2 protein (also known as Breast Cancer Resistance Protein [BCRP], Mitoxantrone Resistance Protein [MXR], and Placenta-Specific ABC transporter [ABCP]) is a primary active transporter that belongs to the ATP-binding cassette (ABC) protein superfamily (<xref ref-type="bibr" rid="bib8">Doyle et al., 1998</xref>). ABCG2 can expel a large variety of chemically unrelated molecules, mainly hydrophobic or amphipathic compounds from cells, including chemotherapeutic drugs and toxic metabolic side-products such as pheophorbide A (<xref ref-type="bibr" rid="bib23">Jonker et al., 2002</xref>), estrone-3-sulfate (E3S) (<xref ref-type="bibr" rid="bib52">Suzuki et al., 2003</xref>), and uric acid (<xref ref-type="bibr" rid="bib66">Woodward et al., 2009</xref>). ABCG2 is expressed in tissues with barrier functions including the blood-brain barrier, blood-testis barrier, intestine, liver, placenta, kidneys, and mammary glands (<xref ref-type="bibr" rid="bib8">Doyle et al., 1998</xref>; <xref ref-type="bibr" rid="bib10">Fetsch et al., 2006</xref>; <xref ref-type="bibr" rid="bib59">van Herwaarden and Schinkel, 2006</xref>). Because of its tissue localization and its broad substrate spectrum, ABCG2 plays an important role in the absorption, distribution, elimination, and toxicity (ADME-Tox) of chemotherapeutic drugs used for the treatment of various diseases (<xref ref-type="bibr" rid="bib13">Giacomini et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Sarkadi et al., 2006</xref>). In addition, the expression of ABCG2 in tumor tissues, especially in the so-called tumor stem cells or drug-tolerant persister cells, correlates with an unfavorable prognosis of tumor chemotherapy (<xref ref-type="bibr" rid="bib6">Ding et al., 2010</xref>). On the other hand, genetic polymorphisms leading to decreased expression and/or impaired function of ABCG2 may result in various pathological conditions (recently reviewed in <xref ref-type="bibr" rid="bib17">Homolya, 2021</xref>). These include altered therapy responses, drug-related toxic reactions, as well as hyperuricemia and gout (<xref ref-type="bibr" rid="bib19">Ishikawa et al., 2013</xref>), since ABCG2 is also a key player of the intestinal uric acid elimination pathway (<xref ref-type="bibr" rid="bib66">Woodward et al., 2009</xref>; <xref ref-type="bibr" rid="bib29">Köttgen and Köttgen, 2021</xref>).</p><p>ABCG2 is a ‘half-transporter’, consisting of an N-terminal nucleotide-binding domain (NBD), followed by a C-terminal transmembrane domain (TMD) that form homodimers in the plasma membrane to obtain a functional transporter (<xref ref-type="bibr" rid="bib25">Kage et al., 2002</xref>). Although the substrate specificity of ABCG2 partially overlaps with that of other drug transporting ABC proteins, sequence similarity is limited to the evolutionarily conserved NBDs. In all ABC transporters, ATP is bound by the Walker A and B motifs of one NBD and by the signature sequence of the other NBD, resulting in a close interaction of the two NBDs, which is often referred to as ‘sandwich-dimer’ (<xref ref-type="bibr" rid="bib31">Locher, 2009</xref>). The molecular mechanism of action of ABC transporters has intrigued scientists for many years. Recent publications of high-resolution cryogenic electron microscopy (cryo-EM) structures have allowed the interrogation of molecular details with atomic precision. According to the widely accepted idea, uphill transport of substrates is linked to conformational changes of the TMDs, which are regulated by the ATP-dependent formation and separation of the NBD ‘sandwich-dimer.’ In the absence of ATP, <italic>apo</italic>-ABCG2 adopts an inward-facing (IF) state, wherein the transmembrane cavity is open toward the cytosolic side, with the central four transmembrane helices (TH2, TH5, TH2′, and TH5′) forming a large drug-binding pocket (<italic>cavity 1</italic>) accessible for substrate binding (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). ATP-bound ABCG2 is in an outward-facing (OF) state, allowing the release of substrates to the extracellular side (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The IF structure contains two substrate-binding cavities: a large central cavity at the cytoplasmic side (<italic>cavity 1</italic>) and an additional cavity (<italic>cavity 2</italic>) located toward the extracellular part of ABCG2 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The two cavities are separated by L554 and L555, which form a tight hydrophobic seal at the top of <italic>cavity 1,</italic> preventing the entry of substrates to <italic>cavity 2</italic> in the IF conformation (<xref ref-type="bibr" rid="bib56">Taylor et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Khunweeraphong et al., 2017</xref>). In other ABCG2 IF structures captured in the presence of substrates or inhibitors, <italic>cavity 1</italic> is occupied by a substrate molecule or either one or two inhibitor molecules (<xref ref-type="bibr" rid="bib20">Jackson et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Orlando and Liao, 2020</xref>). The ATP-free IF state can be detected by the conformation-sensitive monoclonal antibody 5D3 (<xref ref-type="bibr" rid="bib56">Taylor et al., 2017</xref>), which recognizes two composite epitopes formed by extracellular loops (<xref ref-type="fig" rid="fig1">Figure 1C and E</xref>) that are disengaged in the OF state (<xref ref-type="fig" rid="fig1">Figure 1D and F</xref>). The structure of the OF conformer could only be captured by using the E211Q catalytic glutamate mutant ABCG2 variant. In the ATP-bound conformer of this mutant protein, <italic>cavity 1</italic> is completely collapsed, the di-leucine gate is closed, while <italic>cavity 2</italic> is open to the extracellular side of the plasma membrane (<xref ref-type="bibr" rid="bib34">Manolaridis et al., 2018</xref>). However, mutation of the catalytic glutamate may affect the energetics of conformational changes in ABC transporters; thus, it may be argued that the OF state of the E211Q mutant ABCG2 observed in the presence of ATP does not represent a true catalytic intermediate (<xref ref-type="bibr" rid="bib34">Manolaridis et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Lusvarghi et al., 2021</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The IF and OF conformers of ABCG2.</title><p>A slice through IF (<bold>A</bold>) and OF (<bold>B</bold>) ABCG2 shows the lower and upper cavity and reveal their volume changes induced by the transition. Two rotationally symmetric 5D3 epitopes are formed in the IF conformation (<bold>C, E</bold>) and are absent in the OF conformation of ABCG2 (<bold>D, F</bold>). Panels (<bold>C</bold>) and (<bold>D</bold>) show an extracellular view of the 5D3-bound IF (PDB ID: 6ETI), and the OF (PDB ID: 6HBU) ABCG2 conformations, respectively. A side view of the IF (<bold>E</bold>) and the OF (<bold>F</bold>) ABCG2 is also shown. The two protomers of ABCG2 are colored in pink and green in cartoon backbone and transparent surface rendering. The two epitopes are highlighted in blue and orange, and include all residues that are in direct contact with the 5D3 Fab (white) in the 6ETI cryo-EM structure. The membrane boundaries are indicated by dashed lines. cryo-EM, cryogenic electron microscopy; IF, inward-facing; OF, outward-facing.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig1-v1.tif"/></fig><p>Despite the plethora of new ABCG2 structures, several long-standing questions concerning the intramolecular crosstalk between the substrate binding and the nucleotide-binding sites remain unanswered. For example, the intramolecular mechanism by which transported substrates stimulate the ATPase activity has not been identified (<xref ref-type="bibr" rid="bib42">Ozvegy et al., 2001</xref>; <xref ref-type="bibr" rid="bib47">Sarkadi et al., 1992</xref>; <xref ref-type="bibr" rid="bib57">Telbisz et al., 2012</xref>). Similarly, there is no universal agreement on how conformational changes induced by nucleotide binding and hydrolysis result in the decrease of drug binding affinity and lead to the release of the transported substrate. The prevailing view is that ATP binding leads to the formation of the closed NBD ‘sandwich-dimer,’ switching the TMDs from the IF to the OF state, resulting in a concomitant decrease of substrate affinity (<xref ref-type="bibr" rid="bib37">McDevitt et al., 2008</xref>). In that scenario, the role of ATP hydrolysis is to reset the transporter to the high substrate affinity IF state by initiating the dissociation of the closed NBD dimer (<xref ref-type="bibr" rid="bib28">Khunweeraphong et al., 2019</xref>). However, an alternative model states that nucleotide binding is not sufficient, and the IF-OF transition requires ATP hydrolysis (<xref ref-type="bibr" rid="bib26">Kapoor et al., 2018</xref>).</p><p>Since ABC transporters are very sensitive to the composition of their plasma membrane environment (<xref ref-type="bibr" rid="bib21">Januliene and Moeller, 2020</xref>; <xref ref-type="bibr" rid="bib44">Pál et al., 2007</xref>; <xref ref-type="bibr" rid="bib4">Bordignon et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Romsicki and Sharom, 1998</xref>), here we use fluorescence-based methods to study intramolecular crosstalk in live cells or semi-permeabilized cells, where ABCG2 molecules are present in their quasi-natural environment, in the undisturbed context of the plasma membrane (<xref ref-type="bibr" rid="bib3">Bársony et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Goda et al., 2020</xref>). To address how changes of TMD conformation and substrate binding are coupled to ATP binding and hydrolysis, we quantify binding of the conformation-sensitive 5D3 antibody (<xref ref-type="bibr" rid="bib43">Ozvegy-Laczka et al., 2005</xref>). To characterize drug binding, we introduce confocal microscopy- and fluorescence correlation spectroscopy (FCS)-based assays. By measuring substrate binding and reactivity to 5D3, we show that nucleotide binding drives ABCG2 from a high to a low substrate-affinity state and find that this switch coincides with the flip from the IF to the OF conformation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>MDCK II cells express fully functional ABCG2 and ABCG2-GFP</title><p>ABCG2 and its N-terminally GFP-tagged variant (ABCG2-GFP) were expressed at comparable levels in MDCK II cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). In accordance with literature data (<xref ref-type="bibr" rid="bib39">Orbán et al., 2008</xref>; <xref ref-type="bibr" rid="bib15">Haider et al., 2011</xref>), the transport activity of ABCG2 was not influenced by the GFP-tag (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>). Previous observations showed that ABCG2 inhibitors, such as Ko143, can enhance 5D3 mAb binding by shifting the equilibrium to the IF state (<xref ref-type="bibr" rid="bib43">Ozvegy-Laczka et al., 2005</xref>; <xref ref-type="bibr" rid="bib57">Telbisz et al., 2012</xref>). Accordingly, in the plasma membrane of untreated live cells, ABCG2-GFP and ABCG2 exhibited comparably low 5D3-reactivity, which was increased in a similar extent by Ko143 treatment (<xref ref-type="fig" rid="fig2">Figure 2E–G</xref>), supporting the notion that the GFP-tag does not modify the conformational response of ABCG2.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Functional characterization of human ABCG2 and ABCG2-GFP.</title><p>Western blot showing comparable expression of ABCG2 and ABCG2-GFP in MDCK II cells using the BXP-21 anti-ABCG2 mAb (<bold>A</bold>). ABCG2 and ABCG2-GFP expressing cells show decreased mitoxantrone (MX) accumulation, which is reversed to the level of the ABCG2-negative cells by 2 µM Ko143 (<bold>B–D</bold>). 2 µM Ko143 pre-treatment causes an increase in the 5D3-reactivity of ABCG2 (<bold>F</bold>) and ABCG2-GFP (<bold>G</bold>) expressing cells. ABCG2-negative cells show only a negligible 5D3 binding that is not affected by Ko143 (<bold>E</bold>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source Data to <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83976-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig2-v1.tif"/></fig></sec><sec id="s2-2"><title>Nucleotide binding is sufficient to trigger the switch from the 5D3-reactive IF conformation to a 5D3-dim OF conformation</title><p>To study the nucleotide-dependent conformation changes of ABCG2, we systematically changed the intracellular nucleotide concentrations in semi-permeabilized cells. In accordance with an ATP-regulated switch of the TMD conformation, increasing ATP/Mg<sup>2+</sup> concentrations gradually decreased the 5D3-A647-reactivity of ABCG2-positive cells, with practically zero staining at high ATP/Mg<sup>2+</sup> concentrations (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). To prevent nucleotide hydrolysis, ATP was either added in the absence of Mg<sup>2+</sup> (ATP+EDTA; <xref ref-type="fig" rid="fig3">Figure 3C and D</xref>), on ice (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>), or ATP was replaced with the non-hydrolyzable ATP analog AMP-PNP (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>). Interestingly, the conformational change driving ABCG2 into a 5D3-dim (i.e., 5D3 non-reactive) state also occurred in the absence of ATP hydrolysis and showed similar nucleotide concentration dependence (see <xref ref-type="table" rid="table1">Table 1</xref>). These results indicate that the 5D3-dim and 5D3-reactive conformations correspond to the OF and IF conformations as observed in ATP-bound and nucleotide-free crystal structures, respectively (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Nucleotide dependence of 5D3-reactivity.</title><p>MDCK-ABCG2 cells were permeabilized to allow the titration of intracellular nucleotide concentrations. Dose-response curves of 5D3 binding with increasing concentrations of ATP/Mg<sup>2+</sup> (panels (<bold>A</bold>), and (<bold>B</bold>)), ATP in the presence of EDTA (panels (<bold>C</bold>) and (<bold>D</bold>)), AMP-PNP/Mg<sup>2+</sup> (panels (<bold>G</bold>) and (<bold>H</bold>)), or ADP/Mg<sup>2+</sup> (panels (<bold>I</bold>) and (<bold>J</bold>)) were obtained in the presence or absence of Vi (<italic>left</italic> panels) or BeFx (<italic>right</italic> panels). Samples were pre-treated with nucleotides at 37°C for 10 min, then further incubated with 5 µg/ml 5D3-A647 at 37°C for 20 min except for (panels (<bold>E</bold>) and (<bold>F</bold>)), where all the treatments were carried out on ice. In case of nucleotide trapping, permeabilized cells were co-treated with nucleotides and BeFx or Vi at 37°C for 30 min, then un-trapped nucleotides were washed out and 5D3 labeling was carried out on ice for 45 min. Representative curves are shown from three to five independent experiments. The small inserts in panel (<bold>A</bold>) depict the IF and OF conformations of ABCG2. IF, inward-facing; OF, outward-facing.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig3-v1.tif"/></fig><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Apparent nucleotide affinities (K<sub>A</sub>) determined in 5D3-reactivity experiments.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Source Data to <xref ref-type="table" rid="table1">Table 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83976-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Treatment</th><th align="left" valign="bottom" colspan="2">Conditions</th><th align="left" valign="bottom" rowspan="2">K<sub>A</sub> (mM ± SD)</th><th align="left" valign="bottom" rowspan="2">n</th><th align="left" valign="bottom" rowspan="2">Statistical comparisons to ATP/Mg<sup>2+</sup> (1st row)</th><th align="left" valign="bottom" rowspan="2">Figure</th></tr><tr><th align="left" valign="bottom">Temp.</th><th align="left" valign="bottom">Mg<sup>2+</sup></th></tr></thead><tbody><tr><td align="left" valign="bottom"><underline>ATP</underline></td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">4.15 ± 1.08</td><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">–</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3A</xref></td></tr><tr><td align="left" valign="bottom">ATP+Vi</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">0.34 ± 0.25</td><td align="char" char="." valign="bottom">11</td><td align="left" valign="bottom">p &lt; 0.001</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3A</xref></td></tr><tr><td align="left" valign="bottom">ATP+BeFx</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">0.40 ± 0.06</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">p &lt; 0.001</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3B</xref></td></tr><tr><td align="left" valign="bottom">ATP</td><td align="left" valign="bottom">37°C</td><td align="left" valign="bottom">−</td><td align="char" char="plusmn" valign="bottom">3.69 ± 0.49</td><td align="char" char="." valign="bottom">7</td><td align="left" valign="bottom">ns</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3C</xref></td></tr><tr><td align="left" valign="bottom">ATP+Vi</td><td align="left" valign="bottom">37°C</td><td align="left" valign="bottom">−</td><td align="char" char="plusmn" valign="bottom">3.77 ± 0.38</td><td align="char" char="." valign="bottom">4</td><td align="left" valign="bottom">ns</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3C</xref></td></tr><tr><td align="left" valign="bottom">ATP+BeFx</td><td align="left" valign="bottom">37°C</td><td align="left" valign="bottom">−</td><td align="char" char="plusmn" valign="bottom">3.20 ± 0.15</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">ns</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3D</xref></td></tr><tr><td align="left" valign="bottom">ATP</td><td align="left" valign="bottom">4°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">4.38 ± 0.24</td><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">ns</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3E</xref></td></tr><tr><td align="left" valign="bottom">ATP+Vi</td><td align="left" valign="bottom">4°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">4.01 ± 0.23</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">ns</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3E</xref></td></tr><tr><td align="left" valign="bottom">ATP+BeFx</td><td align="left" valign="bottom">4°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">4.06 ± 0.46</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">ns</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3F</xref></td></tr><tr><td align="left" valign="bottom">AMP-PNP</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">5.29 ± 0.22</td><td align="char" char="." valign="bottom">2</td><td align="left" valign="bottom">ns</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3G</xref></td></tr><tr><td align="left" valign="bottom">AMP-PNP+Vi</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="." valign="bottom">4.91</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">nd</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3G</xref></td></tr><tr><td align="left" valign="bottom">AMP-PNP+BeFx</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="." valign="bottom">5.88</td><td align="char" char="." valign="bottom">1</td><td align="left" valign="bottom">nd</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3H</xref></td></tr><tr><td align="left" valign="bottom">ADP</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">7.37 ± 2.31</td><td align="char" char="." valign="bottom">6</td><td align="left" valign="bottom">p &lt; 0.001</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3I</xref></td></tr><tr><td align="left" valign="bottom">ADP+Vi</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">0.44 ± 0.10</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">p &lt; 0.001</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3I</xref></td></tr><tr><td align="left" valign="bottom">ADP+BeFx</td><td align="left" valign="bottom">37°C</td><td align="char" char="plus" valign="bottom">+</td><td align="char" char="plusmn" valign="bottom">0.57 ± 0.32</td><td align="char" char="." valign="bottom">3</td><td align="left" valign="bottom">p &lt; 0.001</td><td align="char" char="." valign="bottom"><xref ref-type="fig" rid="fig3">Figure 3J</xref></td></tr></tbody></table></table-wrap><p>By replacing the cleaved gamma phosphate following ATP hydrolysis, phosphate analogs, such as vanadate (Vi) or beryllium fluoride (BeFx), trap ABC transporters in a stable ternary complex (ABCG2-ADP-Vi/BeFx). Based on different geometries of myosin structures obtained with transition state analogs, the BeFx- or Vi-trapped post-hydrolytic complexes are believed to represent pre- and post-hydrolytic conformations, respectively (<xref ref-type="bibr" rid="bib50">Smith and Rayment, 1996</xref>, <xref ref-type="bibr" rid="bib11">Fisher et al., 1995</xref>; <xref ref-type="bibr" rid="bib54">Szakács et al., 2000</xref>). Co-treatment with Vi or BeFx increased the apparent nucleotide affinity of ABCG2 about 10-fold (<xref ref-type="table" rid="table1">Table 1</xref>) in conditions permitting ATP hydrolysis (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>), confirming that both phosphate analogs can form stable ADP-trapped complexes with ABCG2. When ATP hydrolysis was prevented, the phosphate analogs did not have any effect on the <italic>K<sub>A</sub></italic> values (<xref ref-type="fig" rid="fig3">Figure 3C–H</xref> and <xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Similar to the bacterial ABC transporter MsbA (<xref ref-type="bibr" rid="bib38">Moeller et al., 2015</xref>), ADP/Mg<sup>2+</sup> could also induce the IF to OF switch, albeit at slightly higher concentrations (K<sub>A</sub> = 7.38 ± 2.31 mM) compared to ATP/Mg<sup>2+</sup> (see also <xref ref-type="table" rid="table1">Table 1</xref>). Moreover, nucleotide trapping occurred in the presence of phosphate analogs and ADP/Mg<sup>2+</sup> (<xref ref-type="fig" rid="fig3">Figure 3I–J</xref>). The K<sub>A</sub> values obtained with ADP/Mg<sup>2+</sup> and Vi (K<sub>A</sub> = 0.44 ± 0.1 mM) or BeFx (K<sub>A</sub> = 0.57 ± 0.32 mM) did not differ from the K<sub>A</sub> values of trapping reactions starting from ATP/Mg<sup>2+</sup>. However, in the trapping reactions with ADP/Mg<sup>2+</sup>, about 30% of ABCG2 molecules remained in a 5D3-reactive state even in the presence of very high nucleotide concentrations. This observation may suggest that the ternary complex resulting from ADP/Mg<sup>2+</sup> is different (i.e., less stable, possessing a shorter lifetime compared to the complex produced from ATP/Mg<sup>2+</sup> in the hydrolytic cycle) and therefore the trapping reaction occurs with lower efficiency. Since in energized cells the cytosolic ATP concentration is more than 10-fold higher compared to ADP concentrations (<xref ref-type="bibr" rid="bib65">Williams et al., 1993</xref>), these results indicate that in live cells, (i) the switch from the 5D3-reactive IF to a 5D3-dim OF conformation is induced by ATP binding; and (ii) resetting to the 5D3-reactive IF conformation can only occur after the release of the hydrolysis products.</p></sec><sec id="s2-3"><title>Substrates increase the rate of formation of the Vi- or BeFx-trapped species</title><p>Transported substrates increase the turnover rate of ATP hydrolysis in many ABC transporters including ABCB1 and ABCG2 (<xref ref-type="bibr" rid="bib47">Sarkadi et al., 1992</xref>; <xref ref-type="bibr" rid="bib57">Telbisz et al., 2012</xref>). Progressive accumulation of the transporter molecules in the stable Vi- or BeF<sub>x</sub>-trapped post-hydrolytic states represents a partial reaction of the catalytic cycle in ABC transporters (<xref ref-type="bibr" rid="bib53">Szabó et al., 1998</xref>). Accordingly, the accumulation of ABCG2 in the Vi- or BeFx-trapped post-hydrolytic complex was accelerated by substrates (<xref ref-type="fig" rid="fig4">Figure 4</xref>). E3S and quercetin induced an about a fivefold increase in the rate of the trapping reaction (for t<sub>1/2</sub> values, see <xref ref-type="fig" rid="fig4">Figure 4B</xref>), which is consistent with the extent of stimulations achieved by these compounds in the ATPase assay (<xref ref-type="bibr" rid="bib57">Telbisz et al., 2012</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Effect of transported substrates on the kinetics of the formation of the Vi- and BeFx-trapped complexes.</title><p>Permeabilized MDCK-ABCG2 cells were pre-treated or not with 10 µM quercetin or E3S for 10 min at 37°C and then further incubated with 0.5 mM ATP/Mg<sup>2+</sup> or ADP/Mg<sup>2+</sup> in the presence of Vi or BeFx. Samples taken at different time points were stained with 5 µg/ml 5D3-A647 on ice for 45 min. Panel (<bold>A</bold>) shows a representative Vi-trapping experiment in the absence or presence of E3S, while panel (<bold>B</bold>) summarizes the t<sub>1/2</sub> values calculated from the exponential fit of the kinetic curves (see Materials and methods). Mean ± SD of 3–5 independent experiments is shown. Significant differences compared to substrate untreated samples are shown by ***: p &lt; 0.001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source Data to <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83976-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig4-v1.tif"/></fig><p>The relatively long t<sub>1/2</sub> values compared to the total cycle time, which is in the order of 100 ms (as inferred from ATPase data <xref ref-type="bibr" rid="bib68">Yu et al., 2021</xref>), suggest that formation of a stable post-hydrolysis complex by phosphate mimicking anions is a low-probability event. The increased rate of the trapping reaction in the presence of substrates may be explained by a higher turnover of the ATPase cycle, or a longer duration of the Vi- or BeFx-“sensitive” state, that is between the dissociation of the cleaved phosphate and the disassembly of the NBD dimer. Consistently, trapping reactions starting from ADP/Mg<sup>2+</sup> were not accelerated by quercetin or E3S (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), suggesting that substrates do not affect the overall stability or lifespan of the ADP-bound, phosphate analog-sensitive ABCG2 conformer. This can happen, if substrates similarly accelerate the formation and the dissociation of the ADP-bound conformer, or alternatively, they do not have any effect on these processes.</p></sec><sec id="s2-4"><title>Substrates accelerate the IF to OF transition of ABCG2</title><p>With the aim to pinpoint the transition that is accelerated by transported substrates, in the following experiments, we studied how nucleotides and substrates affect the kinetics of the IF to OF transition detected by a shift in 5D3 binding. To align ABCG2 molecules in an IF state, semi-permeabilized (nucleotide-free) MDCK cells expressing ABCG2 were pre-labeled with 5D3-A647 antibody. Unbound 5D3-A647 molecules were removed, and cells were incubated at 37°C in a sufficiently large volume to prevent rebinding of the antibody. Under these conditions, we observed a gradual decrease of the 5D3-A647 fluorescence of cells, which was completely prevented by Ko143 treatment, supporting the notion that the ABCG2 molecules are intrinsically dynamic, while Ko143 stabilizes them in the IF 5D3-reactive conformation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The dissociation rate of the antibody was significantly enhanced in the presence of transported substrates or ATP/Mg<sup>2+</sup> (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). However, the largest (about fivefold) decrease of the t<sub>1/2</sub> values corresponding to the half-life of the 5D3-bound ABCG2 conformer was observed when substrates were co-administered with ATP/Mg<sup>2+</sup> (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Effects of substrates and nucleotides on the kinetics of 5D3 dissociation when substrates were added simultaneously with nucleotides (<bold>A, B</bold>), or prior to nucleotides (<bold>C</bold>).</title><p>Permeabilized MDCK-ABCG2 cells were pre-labeled with 5D3-A647 in the absence (panels (<bold>A</bold>) and (<bold>B</bold>)) or presence (panel (<bold>C</bold>)) of substrates (10 µM quercetin or 10 µM E3S) for 20 min at 37°C. After removal of the unbound antibody, cells were further incubated with 3 mM ATP/Mg<sup>2+</sup> or AMP-PNP/Mg<sup>2+</sup> in the absence or presence of substrates. Panel (<bold>A</bold>) shows representative 5D3 dissociation curves in the indicated conditions, while panels (<bold>B</bold>) and (<bold>C</bold>) summarizes the t<sub>1/2</sub> values calculated from the exponential fit of the dissociation curves (see Materials and methods). Means ± SD of 3–5 independent experiments are shown. Significant differences compared to untreated samples (first column) are shown by <sup>###</sup>: p &lt; 0.001 or <sup>##</sup>: p &lt; 0.01. Significant differences compared to only nucleotide-treated samples are indicated by ***: p &lt; 0.001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source Data to <xref ref-type="fig" rid="fig5">Figure 5B and C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83976-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig5-v1.tif"/></fig><p>In further experiments, intracellular nucleotide pools were replenished with a non-hydrolyzable ATP analog AMP-PNP/Mg<sup>2+</sup> (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In the absence of ATP hydrolysis, ABCG2 molecules undergo IF to OF transition (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>), and the backward transition to the IF state has an extremely low probability. The time dependence of the AMP-PNP/Mg<sup>2+</sup>-induced 5D3 dissociation was comparable to that obtained with ATP/Mg<sup>2+</sup> supporting that the antibody dissociation kinetics observed either in the presence of ATP/Mg<sup>2+</sup> or AMP-PNP/Mg<sup>2+</sup> may reflect the first nucleotide-induced IF to OF transition of ABCG2 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Strikingly, when co-administered with AMP-PNP/Mg<sup>2+</sup>, the same substrates did not increase further the dissociation rate of 5D3, suggesting that the NBD dimer formation induced by AMP-PNP/Mg<sup>2+</sup> binding switches ABCG2 into the low drug binding affinity state (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). However, a similar decrease of the t<sub>1/2</sub> values was observed when substrates were added before AMP-PNP/Mg<sup>2+</sup> treatment (compare <xref ref-type="fig" rid="fig5">Figure 5B and C</xref>), indicating that transition to the OF state can also be accelerated by substrates with AMP-PNP/Mg<sup>2+</sup> treatment. Collectively, the above data imply that substrate binding at the TMDs induces a structural change in the transporter that can facilitate the nucleotide-dependent NBD dimer formation and the concomitant IF to OF transition, probably by reducing the energy barrier of the above conformational changes (<xref ref-type="bibr" rid="bib40">Orelle et al., 2022</xref>).</p></sec><sec id="s2-5"><title>The nucleotide-free IF conformation of ABCG2 has higher substrate affinity compared to the Vi-trapped post-hydrolytic conformation</title><p>In the following experiments, we visualized the subcellular localization of ABCG2-GFP and the fluorescent ABCG2 substrate mitoxantrone (MX) by using confocal microscopy. In accordance with previous observations (<xref ref-type="bibr" rid="bib16">Homolya et al., 2011</xref>), at low concentrations, MX only stained poorly the MDCK ABCG2-GFP cells, while ATP depletion, Ko143 or Vi treatments increased the intracellular accumulation of MX (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Interestingly, ATP-depleted cells exhibited strong plasma membrane staining by MX (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Plasma membrane staining by MX in both native and ATP-depleted cells was abolished by treatment with the competitive inhibitor Ko143, suggesting that red fluorescence in the plasma membrane of ATP-depleted cells reflects MX binding to ABCG2 molecules. To quantify the fraction of MX-bound ABCG2 molecules, we calculated the Pearson’s correlation coefficients (PCC) between the MX and ABCG2-GFP signals in pixels representing the plasma membrane. Since the ABCG2-GFP signal was unchanged during the course of the different treatments (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), the correlation coefficients depend mostly on MX binding to the transporter. In ATP-depleted cells, the high correlation values indicate that the majority of ABCG2 molecules reside in an MX-bound conformation (PCC = 0.72 ± 0.12) (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). The correlation between the two signals strongly decreased in the presence of Ko143 (PCC = –0.1 ± 0.18), suggesting displacement of MX from the substrate binding site of the transporter by the competitive inhibitor. Similar results were obtained when ATP depletion was combined with Ko143 treatment (PCC = –0.04 ± 0.17). Binding of MX to ABCG2 was also suppressed by Vi (PCC = 0.18 ± 0.13), which is consistent with the notion that the post-hydrolytic ABCG2 conformer possesses low substrate affinity. Interestingly, in untreated cells, we measured significantly higher co-localization between the MX and ABCG2-GFP signals (PCC = 0.3 ± 0.12) than in Ko143-treated cells, suggesting that in the plasma membrane of live cells, a significant subset of ABCG2 molecules resides in an MX-bound IF state.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Cellular distribution of MX (red) in MDCK cells expressing ABCG2-GFP (green) in response to ATP depletion and/or Ko143 or Vi treatment (<bold>A</bold>).</title><p>All treatments increased the intracellular MX fluorescence intensity (<bold>B</bold>), while the ABCG2-GFP fluorescence intensity in the plasma membrane remained unchanged (<bold>C</bold>). Pearson’s correlation coefficients between the intensity distributions of MX and ABCG2-GFP in the plasma membrane pixels reveal the stabilization of a high-affinity substrate binding ABCG2 conformation in energy-deprived cells (<bold>D</bold>). ATP depletion was induced by 15  min pre-treatment of cells with 10  mM sodium azide and 8  mM 2-deoxy-D-glucose. Ko143, a non-fluorescent, competitive ABCG2 inhibitor, was added 10  min before MX staining. In panels (<bold>B</bold>) and (<bold>C</bold>), bars represent mean ± SD values, while panel (<bold>D</bold>) shows box and whisker plots. For each treatment group, 150–200 cells were analyzed from three to five independent experiments. Significant differences compared to the untreated control are shown by ***: p &lt; 0.001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Source Data to <xref ref-type="fig" rid="fig6">Figure 6B–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83976-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig6-v1.tif"/></fig></sec><sec id="s2-6"><title>MX binding to ABCG2 is confirmed by its reduced mobility using FCS measurements</title><p>As an independent approach to follow MX binding to ABCG2, we measured the mobility of MX in the plasma membrane by FCS. MX molecules bound to ABCG2 are expected to show decreased diffusion compared to free MX (<xref ref-type="bibr" rid="bib18">Horsey et al., 2020</xref>). We analyzed the fluorescence autocorrelation functions (ACFs) of MX (orange) and ABCG2-GFP (green) in the plasma membrane using a two-component model (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Upon ATP depletion, the diffusion coefficient of MX decreased to the level obtained for ABCG2-GFP (<xref ref-type="fig" rid="fig7">Figure 7B</xref>), indicating that MX molecules readily bind to the nucleotide-free IF conformer of ABCG2. In accordance with the data obtained from cellular distributions (<xref ref-type="fig" rid="fig6">Figure 6A and D</xref>), the competitive inhibitor Ko143 prevented MX binding to ABCG2, resulting in the dominance of a high plasma membrane mobility MX population similar to the only MX-treated cells (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Fluorescence autocorrelation functions (<bold>A</bold>) and diffusion constants (<bold>B</bold>) of ABCG2-GFP (green) and MX (orange) in the plasma membrane of intact MDCK cells.</title><p>ABCG2-GFP expressing cells without pre-treatments or following ATP depletion or Ko143 pre-treatment were stained with 100 nM MX for 15 min at 37°C. Each bar shows the mean ± SD for n = 50–100 cells from at least three independent measurements. Significant differences compared to the diffusion constant of ABCG2-GFP (green bar) in the plasma membrane of untreated cells are shown by ***: p &lt; 0.001.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Source Data to <xref ref-type="fig" rid="fig7">Figure 7B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83976-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig7-v1.tif"/></fig></sec><sec id="s2-7"><title>AMP-PNP binding switches ABCG2 to a conformation that is unable to bind MX</title><p>As shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>, permeabilization of cells with streptolysin-O (SLO) synchronizes ABCG2 molecules in a nucleotide-free, 5D3-reactive IF conformation also observed in cryo-EM structures (<xref ref-type="bibr" rid="bib56">Taylor et al., 2017</xref>). When permeabilized cells were treated with MX alone, we measured a strong co-localization between ABCG2-GFP and MX in the plasma membrane (PCC = 0.85 ± 0.05), confirming the high substrate affinity of the IF conformation of ABCG2. Strikingly, pre-incubation of permeabilized cells with 5 mM AMP-PNP/Mg<sup>2+</sup> strongly reduced the co-localization between MX and ABCG2-GFP in the plasma membrane (PCC = –0.1181 ± 0.2019), indicating that the conformational changes induced by AMP-PNP binding prevented MX binding to ABCG2 (<xref ref-type="fig" rid="fig8">Figure 8</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Substrate affinity changes of ABCG2 in permeabilized cells.</title><p>SLO-permeabilized ABCG2-GFP expressing cells were pre-treated or not with 5 mM AMP-PNP/Mg<sup>2+</sup> for 15 min and then stained with 500 nM MX for 15 min at 37°C. Permeabilized cells were identified by PI staining. Box and whisker plots show Pearson’s correlation coefficients of n &gt; 150 cells from three independent experiments. ***p &lt; 0.001 by Kolmogorov-Smirnov test. MX, mitoxantrone; PI, propidium iodide; SLO, streptolysin-O.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Source Data to <xref ref-type="fig" rid="fig8">Figure 8B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83976-fig8-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83976-fig8-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>According to the alternating access model formulated by Jardetzky more than 50 years ago, membrane transporters alternate between IF and OF states, in which the centrally located substrate-binding site is accessible to only one side of the membrane at a time (<xref ref-type="bibr" rid="bib22">Jardetzky, 1966</xref>). In active transporters, such as ABC transporters, accessibility changes are accompanied by a significant change of substrate affinity that is linked to binding and hydrolysis of ATP (<xref ref-type="bibr" rid="bib49">Seeger and van Veen, 2009</xref>). Based on homology models and cryo-EM structures, ABCG2 is believed to alternate between a nucleotide-free IF and a nucleotide-bound OF conformation during its transport cycle (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). The switch between the NBD-dissociated IF and the NBD-associated OF states involves a series of conformational changes that finally result in the uphill transport of substrates. In agreement with cryo-EM studies, we show in nucleotide titration experiments (<xref ref-type="fig" rid="fig3">Figure 3</xref>) that 5D3 exclusively recognizes the nucleotide-free IF conformation of ABCG2 (<xref ref-type="bibr" rid="bib56">Taylor et al., 2017</xref>), as the 5D3 recognized epitope of ABCG2 only forms in the IF conformation, while it is disrupted in the OF conformation (<xref ref-type="fig" rid="fig1">Figure 1C–F</xref>).</p><p>While semi-permeabilized cells provide a unique tool to study ABCG2 in a quasi-natural environment, the antibody-shift assay has several limitations. Because of the conformation selectivity of 5D3, details of the allosteric coupling between the NBDs and TMDs are inferred based on the influence of nucleotides and substrates on the population of ABCG2 molecules in the IF state, without any direct information on the intermediate or OF sates. Still, by modulating the levels of various nucleotide species, we were able to delineate distinct steps of the ATPase cycle, such as nucleotide binding or ATP hydrolysis. Moreover, we characterized MX binding to ABCG2 to better understand the crosstalk between nucleotide and substrate binding. While the interactions of fluorescent substrates with purified ABC transporters have been studied in nanodiscs (<xref ref-type="bibr" rid="bib30">Li et al., 2017</xref>) or styrene maleic acid lipid copolymer particles (<xref ref-type="bibr" rid="bib18">Horsey et al., 2020</xref>), to our knowledge we have applied the FCS technique for the first time to study substrate binding to ABCG2 in its natural plasma membrane environment in live cells.</p><p>In accordance with structural studies, our confocal microscopy experiments carried out in live cells show that the <italic>apo</italic> form of ABCG2 possesses high MX-affinity, while nucleotide binding and the concomitant dimerization of the NBDs induce conformation changes that prevent MX-binding. The simultaneous drop in the 5D3- and MX-binding indicates that the high-to-low switch in drug binding affinity coincides with the transition from the IF to the OF conformation. Ko143, which can displace MX from the substrate binding site (see <xref ref-type="fig" rid="fig6">Figures 6</xref> and <xref ref-type="fig" rid="fig7">7</xref>) also prevents the transition of ABCG2 from the IF to the OF conformation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) in agreement with previous cryo-EM studies (<xref ref-type="bibr" rid="bib41">Orlando and Liao, 2020</xref>; <xref ref-type="bibr" rid="bib68">Yu et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Jackson et al., 2018</xref>). Our data also directly indicate that high-affinity binding of MX requires the IF conformation and that energizing the transporter by nucleotides is not required for substrate binding. The nucleotide titration experiments prove that nucleotide binding (ATP, AMP-PNP, and ADP) and concomitant NBD dimer formation is sufficient to induce the conformational switch to the OF conformation, and that ATP hydrolysis is not essential for the nucleotide-dependent IF-OF transition (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and the high-to-low switch in drug binding affinity (<xref ref-type="fig" rid="fig8">Figure 8</xref>), supporting the results of structural studies carried out using the catalytic glutamate mutant ABCG2 variant (<xref ref-type="bibr" rid="bib34">Manolaridis et al., 2018</xref>). We also observed that in the presence of physiological ATP concentrations, in the context of the plasma membrane of live cells, a small, but significant fraction of ABCG2 molecules reside in the MX-bound state (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) ready to initiate a productive transport cycle. The V<sub>i</sub>-trapped post-hydrolysis state possesses low substrate affinity (<xref ref-type="fig" rid="fig6">Figure 6A and D</xref>), confirming that dissociation of the hydrolysis products is required to switch the transporter from the OF conformation back to the IF conformation and to reset its high substrate affinity.</p><p>Previous studies observed analogous changes of the substrate binding affinity in ABCB1 (<xref ref-type="bibr" rid="bib36">Martin et al., 2001</xref>), ABCC1 (<xref ref-type="bibr" rid="bib46">Rothnie et al., 2006</xref>), and ABCG2 (<xref ref-type="bibr" rid="bib37">McDevitt et al., 2008</xref>) using radioligand binding assays. ABCB1 exists in an equilibrium between OF and IF states, which are readily interconverted by ligand binding (<xref ref-type="bibr" rid="bib35">Marcoux et al., 2013</xref>). A similar, bidirectional interdomain crosstalk between the NBDs and TMDs was observed in human ABCB1 using the UIC2-reactivity assay (<xref ref-type="bibr" rid="bib3">Bársony et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Goda et al., 2020</xref>). The fact that the antibody binding site and the NBDs of the transporters are ~80 Å apart and on opposite sides of the membrane suggests that long-range conformational couplings between the TMD and NBD motions are conserved features among human ABC exporters. However, the similarity in coupling of the ATPase activity and the transport cycles of ABCB1 and ABCG2 is remarkable in view of the differences in the conformational changes of the TMDs and the substrate binding cavities (<xref ref-type="bibr" rid="bib2">Arana and Altenberg, 2019</xref>; <xref ref-type="bibr" rid="bib60">van Wonderen et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Locher, 2016</xref>), and the different modes of the nucleotide-dependent NBD motions (<xref ref-type="bibr" rid="bib51">Stockner et al., 2020</xref>).</p><p>Like several other ABC transporters, ABCG2 possesses significant basal ATPase activity, which is generally increased 2- to 5-fold by transported substrates (<xref ref-type="bibr" rid="bib57">Telbisz et al., 2012</xref>). The increased catalytic turnover is reflected by the enhanced steady-state ATP hydrolysis rate (<xref ref-type="bibr" rid="bib57">Telbisz et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Ozvegy et al., 2001</xref>) and the increased rate at which ABCG2 becomes trapped in the Vi- or BeFx-bound post-hydrolytic states (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>Our experiments demonstrated that 5D3 binding to ABCG2 is reversible, and addition of substrates, ATP/Mg<sup>2+</sup> or their combination can accelerate the kinetics of antibody dissociation. The reversible nature of 5D3 binding also explains previous observations that treatments with saturating concentration of the antibody did not induce complete inhibition of transport and of ATPase activity (<xref ref-type="bibr" rid="bib43">Ozvegy-Laczka et al., 2005</xref>).</p><p>Importantly, 5D3 dissociation experiments carried out in the absence of nucleotides clearly showed that substrate binding alone has an effect on the conformation of ABCG2 (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). When substrates are presented prior to the nucleotides, the IF to OF transition is accelerated. In contrast, when the nucleotide analog AMP-PNP is allowed to bind first, substrates cannot promote the transition (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Thus, substrates accelerate the cumulative step of nucleotide binding, NBD ‘sandwich-dimer’ formation, and the concomitant IF to OF transition, but only when having access to the substrate binding site as present in the IF state. The substrate-induced conformational change might be small as indicated by a recent study, which could not detect these changes as an increase in the proximity ratio of FRET between the NBDs of ABCB1 in permeabilized cells deprived of ATP/Mg<sup>2+</sup> (<xref ref-type="bibr" rid="bib12">Futamata et al., 2020</xref>). Accordingly, in recent cryo-EM studies carried out at turnover conditions (in the presence of substrate and ATP/Mg<sup>2+</sup>), two conformers representing the transition from the IF state to a semi-closed state were identified. These structures revealed that the accessibility of the substrate binding site gradually decreases upon the closure of the NBD dimer (<xref ref-type="bibr" rid="bib68">Yu et al., 2021</xref>), and therefore, substrates should bind to the IF conformer.</p><p>In conclusion, our results indicate that nucleotide binding is the major regulator of TMD conformation in ABCG2. The nucleotide induced IF to OF transition coincides with the high-to-low switch of substrate affinity, and this event precedes ATP hydrolysis. Detailed kinetic analysis of several ABC transporters will be needed to establish differences and similarities of the catalytic mechanisms within the superfamily. In the case of the channel-type ABC protein CFTR (ABCC7), pore opening, believed to correspond to the IF to OF transition, represents the slowest step of the gating cycle (<xref ref-type="bibr" rid="bib61">Vergani et al., 2013</xref>). In contrast, in the case of ABCC1 (<xref ref-type="bibr" rid="bib63">Wang et al., 2020</xref>) and ABCB1 (<xref ref-type="bibr" rid="bib3">Bársony et al., 2016</xref>), the IF to OF transition is not the rate-limiting step of the catalytic cycle. Similarly, <xref ref-type="fig" rid="fig3">Figure 3A and B</xref> reveals that in the presence of saturating concentrations of hydrolyzable ATP, the majority of ABCG2 molecules adopt the 5D3-dim OF conformation, indicating that the IF to OF transition is not the slowest step of the catalytic cycle and consequently it is not the major determinant of the cycle time. Accordingly, in live cells, only a small fraction of ABCG2 molecules is in the substrate-bound IF conformation ready to harvest the energy of ATP for transport, while depletion of ATP increases the proportion of ABCG2 molecules in the IF conformation by prolonging the waiting time before the IF to OF transition (<xref ref-type="fig" rid="fig6">Figure 6A and D</xref>). How can we explain the stimulation of the steady-state ABCG2 ATPase activity by transported substrates? On the one hand, results shown in <xref ref-type="fig" rid="fig5">Figure 5</xref> clearly demonstrate that bound substrates accelerate the IF to OF transition, probably by facilitating the nucleotide-dependent NBD dimer formation. However, a mere speeding of the IF to OF transition cannot significantly increase the turnover rate, suggesting that substrate-mediated stimulation of the ATPase must reflect acceleration of some other step(s). At the same time, results presented in <xref ref-type="fig" rid="fig6">Figures 6</xref>—<xref ref-type="fig" rid="fig8">8</xref> indicate that substrates can no longer bind to the OF, low-substrate-affinity conformation, and therefore their influence on the rate constants of ATP hydrolysis and the concomitant NBD dissociation can be ruled out. This apparent paradox may be resolved by assuming two distinct pre-hydrolytic OF states associated with an uncoupled, basal activity and a coupled, drug transport dependent ATPase activity (<xref ref-type="bibr" rid="bib1">Al-Shawi et al., 2003</xref>; <xref ref-type="bibr" rid="bib7">Doshi and van Veen, 2013</xref>). In the coupled activity pathway, transported substrates increase the catalytic rate of ABCG2 by accelerating the IF-OF transition similar to ABCC1 (<xref ref-type="bibr" rid="bib63">Wang et al., 2020</xref>). In the absence of drugs, the transporter follows a different catalytic path, in which the step limiting the uncoupled ATPase activity follows the IF-OF transition. Eventually, ABCG2 molecules that have reached the NBD ‘sandwich-dimer’ without substrate binding either dissociate without hydrolysis, or undergo a futile ATP hydrolysis cycle to reset the transporter into an IF state with high drug binding affinity. In the future, single molecule-based approaches (<xref ref-type="bibr" rid="bib5">Catipovic et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Josts et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2020</xref>) may provide further insights into the kinetics of the above transitions.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">5D3 (mouse monoclonal)</td><td align="left" valign="bottom">Hybridoma was donated by Brian P. Sorrentino</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Prepared from hybridoma supernatant by affinity chromatography</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">BXP-21 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-58222</td><td align="char" char="." valign="bottom">(1:2500 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">C-2 (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-8432</td><td align="char" char="." valign="bottom">(1:2500 dilution)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG-HRP (polyclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-2005</td><td align="char" char="." valign="bottom">(1:2500 dilution)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Canis familiaris</italic>, dog)</td><td align="left" valign="bottom">MDCK II, (epithelial-like cells from kidney distal tubule)</td><td align="left" valign="bottom">Obtained from Prof. Gerrit van Meer</td><td align="left" valign="bottom">ECACC 00062107</td><td align="left" valign="bottom">Mycoplasma-free</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>, mouse)</td><td align="char" char="." valign="bottom">5D3 hybridoma</td><td align="left" valign="bottom">Donated by Brian P. Sorrentino</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Mycoplasma-free</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mitoxantrone</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# M6545</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ko143</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# K2145</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Quercetin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# Q4951</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Estrone-3-sulfate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# E9145</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ADP</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A2754</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">AMP-PNP</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A2647</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ATP</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A2383</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium-orthovanadate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# S6508</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P2714</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DL-Dithiothreitol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D0632</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Flowing software</td><td align="left" valign="bottom">Turku Centre for Biotechnology</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioscience.fi/services/cell-imaging/flowing-software/">https://bioscience.fi/services/cell-imaging/flowing-software/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MATLAB</td><td align="left" valign="bottom">Mathworks Inc.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.mathworks.com/products/matlab.html">https://www.mathworks.com/products/matlab.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">QuickFit 3.0</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://biii.eu/quickfit-3">https://biii.eu/quickfit-3</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SigmaPlot</td><td align="left" valign="bottom">Systat Software Inc.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://systatsoftware.com/sigmaplot/">https://systatsoftware.com/sigmaplot/</ext-link></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Eight-well chambered coverslip plate</td><td align="left" valign="bottom">ibidi GmbH</td><td align="left" valign="bottom">Cat# 80826-90</td><td align="left" valign="bottom">Imaging chamber for microscopy</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Streptolysin-O (SLO) from Streptococcus pyogenes</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# S5265</td><td align="char" char="." valign="bottom">(250 U/ml)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Alexa 647 succinimidyl ester</td><td align="left" valign="bottom">Life Technologies Inc.</td><td align="left" valign="bottom">Cat# A20006</td><td align="left" valign="bottom">Fluorescent dye</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Propidium iodide</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P4170</td><td align="left" valign="bottom">Fluorescent dye</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SuperSignal West Pico PLUS Chemiluminescent Substrate</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 34579</td><td align="left" valign="bottom">Reagent for protein detection in western blot analysis</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Chemicals</title><p>Cell culture media, supplements, and chemicals were purchased from Sigma-Aldrich (Budapest, Hungary). Alexa 647 succinimidyl ester (A647) was purchased from Life Technologies, Inc (Carlsbad, CA). The 5D3 anti-ABCG2 mAb was prepared from hybridoma supernatants by affinity chromatography. Purity (&gt;97%) was verified by SDS/PAGE. The 5D3 hybridoma cell line was a kind gift from Brian P. Sorrentino (Division of Experimental Hematology, Department of Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, TN). 5D3 antibody was labeled with A647 (5D3-A647) and was separated from the unconjugated dye by gel filtration using a Sephadex G-50 column. The dye-to-protein ratio was approximately 3 for each antibody preparation. Stock solutions of nucleotides were prepared in distilled water at pH 7 (by Tris-Base).</p></sec><sec id="s4-2"><title>Cell lines</title><p>The MDCK II Madin-Darby canine kidney cell line was a kind gift from Gerrit van Meer (Department of Membrane Enzymology, Centre for Biomembranes and Lipid Enzymology Utrecht, The Netherlands). The MDCK II cell lines stably expressing ABCG2 or its N-terminally green fluorescent protein (GFP) tagged variant (<xref ref-type="bibr" rid="bib39">Orbán et al., 2008</xref>) were established using the <italic>Sleeping Beauty</italic> transposon-based gene delivery system (<xref ref-type="bibr" rid="bib9">Erdei et al., 2018</xref>). Cells expressing the transgene at high level were selected based on their 5D3-A647 or GFP fluorescence by repeated flow cytometry sorting using a Becton Dickinson FACSAria III Cell Sorter (Becton Dickinson, Mountain View, CA). Cells were grown as monolayer cultures in Dulbecco’s modified Eagle’s medium supplemented with 0.1 mg/ml penicillin-streptomycin cocktail, 10% heat-inactivated fetal calf serum and 2 mM L-glutamine. Cells were maintained at 37°C in a 5% CO<sub>2</sub> atmosphere and were grown to approximately 80% confluency. Cells were regularly checked for Mycoplasma infection and were found to be negative.</p></sec><sec id="s4-3"><title>Western blot analysis</title><p>Cells (2 × 10<sup>5</sup>) were lysed in 100 µl reducing Laemmli sample buffer (6×) for 10 min at 95 °C. Afterward, the lysates were subjected to SDS-polyacrylamide gel electrophoresis using an 8% polyacrylamide gel and then electroblotted onto a nitrocellulose membrane with a pore size of 0.45  μm (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK). ABCG2 expression was detected by the BXP-21 mouse mAb, while actin was labeled with the C-2 mouse mAb (both from Santa Cruz Biotechnology Inc, Santa Cruz Biotechnology, CA). As a secondary antibody, a goat anti-mouse HRP-conjugated IgG (Santa Cruz Biotechnology Inc, Santa Cruz, CA) was applied. All antibodies were used at 1:2500 dilution. Bands were visualized with SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA) using the FluorChem Q gel documentation system (Alpha Innotech Corp, San Leandro, CA).</p></sec><sec id="s4-4"><title>MX accumulation test</title><p>The transport activity of ABCG2 and ABCG2-GFP was studied using an MX accumulation assay (<xref ref-type="bibr" rid="bib55">Tarapcsák et al., 2017</xref>). Cells (0.5 × 10<sup>6</sup>  ml<sup>-1</sup> in PBS containing 7 mM glucose [gl-PBS]) were pre-incubated in the presence or absence of 2 μM Ko143 for 15 min at 37°C and then stained with 5 μM MX for 30 min. Samples were washed three times with ice-cold gl-PBS containing 0.5% fetal bovine serum (FBS) and stored on ice until flow cytometry measurement. To exclude dead cells from the analysis, samples were stained with propidium iodide (PI).</p></sec><sec id="s4-5"><title>5D3-reactivity assay</title><p>Cells (0.5 × 10<sup>6</sup> ml<sup>−</sup><sup>1</sup> in gl-PBS) were pre-incubated with or without 2 µM Ko143 for 10 min and then further incubated with 5 µg/ml 5D3-A647 monoclonal anti-ABCG2 antibody at 37°C. After 30 min of incubation, samples were washed two times with ice-cold gl-PBS and centrifuged for 5 min at 435<italic>×g</italic> at 4°C. The 5D3-A647 fluorescence intensity of the cells was measured by flow cytometry.</p></sec><sec id="s4-6"><title>Permeabilization of cells with SLO toxin</title><p>SLO (Sigma-Aldrich, Budapest, Hungary) is a pore-forming exotoxin from <italic>Streptococcus pyogenes</italic>. The SLO pores formed in the membrane are permeable to small water-soluble molecules including nucleotides (<xref ref-type="bibr" rid="bib67">Yang et al., 2006</xref>). SLO is an oxygen-labile toxin that is reversibly activated by dithiothreitol (DTT). Cell suspensions (1 × 10<sup>7</sup> cells/ml) were treated with 250 U/ml SLO in the presence of 1 mM DTT, Protease Inhibitor Cocktail (2 mM AEBSF, 0.3 µM aprotinin, 116 µM bestatin, 14 µM E-64, and 1 µM leupeptin), 0.5 mM PMSF, and 1% FBS in gl-PBS at 37 °C for 30 min, which allowed permeabilization of approximately 50% of cells, as it was verified by PI staining. The reaction was stopped with 20 ml PBS containing 1% FBS and the cells were centrifuged at 635×<italic>g</italic> for 5 min at room temperature. Unbound toxin was removed by washing the cells three times with PBS and the cell pellet was resuspended in PBS (<xref ref-type="bibr" rid="bib14">Goda et al., 2020</xref>). The applied 1 mM DTT concentration did not affect the 5D3-reactivity of ABCG2.</p><p>Cells grown in eight-well chambered coverslip plates (ibidi GmbH, Gräfelfing, Germany) for confocal microscopy experiments were permeabilized using 62.5 U/ml SLO in the presence of 1 mM DTT and Protease Inhibitor Cocktail at 37°C for 15 min, in HEPES solution (20 mM HEPES, 123 mM NaCl, 5 mM KCl, 1.5 mM MgCl<sub>2</sub>, and 1 mM CaCl<sub>2</sub>) containing 1% FBS.</p></sec><sec id="s4-7"><title>Determination of apparent affinity of nucleotide binding</title><p>Apparent affinity of nucleotide binding (<italic>K</italic><sub><italic>A</italic></sub>) was determined as described previously (<xref ref-type="bibr" rid="bib3">Bársony et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Goda et al., 2020</xref>). Permeabilized cells (1 × 10<sup>6</sup>ml<sup>−1</sup>) were pre-treated with nucleotides added at different concentrations in the presence of equimolar concentrations of Mg<sup>2+</sup> at 37°C for 10 min and then further incubated with 5 μg/ml 5D3-A647 at 37°C for 20 min. To prevent ATP hydrolysis, ATP was added without Mg<sup>2+</sup> in the presence of 5 mM EDTA or the whole experiment was carried out on ice. In nucleotide trapping experiments, nucleotide treatments were applied together with 0.5 mM sodium orthovanadate (Vi) or BeFx (200 μM BeSO<sub>4</sub> and 1 mM NaF) at 37°C for 30 min. Subsequently, the cells were labeled with 5 μg/ml 5D3-A647 on ice for 45 min after removal of the un-trapped nucleotides by washing them two times with ice-cold PBS. After antibody labeling samples were washed again three times with ice-cold PBS and centrifuged for 5 min at 635×<italic>g</italic> at 4°C. The mean 5D3-A647 fluorescence intensity of the cells was determined by flow cytometry and plotted as a function of the nucleotide concentration. To determine the apparent affinity of ABCG2 for nucleotides (<italic>K</italic><sub><italic>A</italic></sub>), data points were fitted with the four-parameter Hill function, where the <italic>F</italic><sub><italic>min</italic></sub> and <italic>F</italic><sub><italic>max</italic></sub> values represent the minimum and maximum fluorescence intensities, respectively:<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>x</mml:mi><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p></sec><sec id="s4-8"><title>Studying the kinetics of nucleotide trapping by Vi or BeFx</title><p>Permeabilized cells (1 × 10<sup>6</sup> ml<sup>−1</sup>) were incubated with 0.5 mM ATP/Mg<sup>2+</sup> or ADP/Mg<sup>2+</sup> and 0.5 mM V<sub>i</sub> or BeF<sub>x</sub> (200 μM BeSO<sub>4</sub> and 1 mM NaF) in the presence or absence of ABCG2 substrates (10 µM quercetin or 10 µM E3S) in PBS at 37°C. To follow the kinetics of the trapping reaction, 500 μl aliquots was taken at different time points and washed two times with 5 ml ice-cold PBS. After washing, the samples were resuspended in 500 μl ice-cold PBS and labeled with 5 μg/ml 5D3-A647 at 4°C for 45 min. The 5D3-A647 fluorescence intensity of the samples (<italic>F</italic>) was plotted as a function of time (<italic>t</italic>). The <italic>t</italic><sub><italic>1/2</italic></sub> values, representing the half-life of the 5D3-reactive ABCG2 conformation, were calculated from an exponential fit of the data points according to the following equation:<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mrow><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>t</mml:mi><mml:mo>×</mml:mo><mml:mfrac><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:math></disp-formula></p><p>Wherein <italic>F</italic><sub>0</sub> is the difference between the zero and infinite time points of the curve and <italic>c</italic> is the background fluorescence intensity of cells.</p></sec><sec id="s4-9"><title>5D3 dissociation</title><p>Permeabilized MDCK-ABCG2 cells (1 × 10<sup>6</sup> ml<sup>−1</sup>) were pre-labeled with 5D3-A647 in the presence or absence of 10 µM quercetin or 10 µM E3S for 20 min at 37°C. After removing the unbound 5D3-A647, cells (1 × 10<sup>5</sup> ml<sup>−1</sup>) were further incubated with 3 mM ATP/Mg<sup>2+</sup> or AMP-PNP/Mg<sup>2+</sup> in the absence or presence of the above substrates at 37°C. To study the kinetics of 5D3 dissociation, 500 μl aliquots were taken at regular intervals and washed two times with ice-cold PBS. The 5D3-A647 fluorescence intensity of the cells was measured by flow cytometry and plotted as a function of time (t). The t<sub>1/2</sub> values, representing the half-life of the 5D3-reactive ABCG2 conformation, were calculated from an exponential fit of the data points using <xref ref-type="disp-formula" rid="equ2">Equation 2</xref>.</p></sec><sec id="s4-10"><title>Flow cytometry</title><p>Flow cytometry analysis was carried out using a Becton Dickinson FACS Array flow cytometer (Becton Dickinson, Mountain View, CA). A 635  nm laser was used for the excitation of MX and A647 and their fluorescence was detected in the red channel through a 661/16  nm bandpass filter, while a 532  nm laser was used for the excitation of PI and the emitted light was detected using a 585/42  nm bandpass filter. Cell debris was excluded from analysis on the basis of FSC and SSC signals. Fluorescence signals of 2 × 10<sup>5</sup> cells/sample were collected in logarithmic mode, and the cytofluorimetric data were analyzed using the Flowing software (Cell Imaging Core, Turku Centre for Biotechnology, Turku, Finland).</p></sec><sec id="s4-11"><title>Confocal laser scanning microscopy and fluorescence co-localization analysis</title><p>To assess the co-localization of ABCG2-GFP and the fluorescent ABCG2 substrate MX in the plasma membrane of MDCK cells, we carried out confocal laser scanning microscopy (CLSM) experiments. Measurements were performed in eight-well chambered coverslip plates (ibidi GmbH, Gräfelfing, Germany). ATP depletion of intact cells was induced by a 15 min pre-treatment with 8 mM 2-deoxy-D-glucose and 10 mM sodium azide in glucose-free medium. ATP-depleted or non-ATP-depleted cells were pre-treated with 2 µM Ko143 or 0.5 mM Vi for 15 min, stained with 500 nM MX for 15 min at 37°C and then washed three times with HEPES solution. SLO-permeabilized cells were pre-stained with 6 µg/ml PI, then further incubated with 500 nM MX for 15 min at 37°C in the presence or absence of 5 mM AMP-PNP and subsequently washed three times with HEPES solution.</p><p>Fluorescence images were acquired with a Nikon A1 Eclipse Ti2 Confocal Laser-Scanning Microscope (Nikon, Tokyo, Japan) using a Plan Apo 60× water objective (NA = 1.27). Laser lines of 488 and 647 nm were used for the excitation of ABCG2-GFP and MX, while fluorescence emissions were detected through band pass filters of 500–550 and 660–740 nm, respectively. All the images were recorded with the same settings of the equipment, such as same high voltages, laser powers and pinhole. Images were acquired in sequential mode to minimize the crosstalk between channels. Images of approximately 1-μm-thick optical sections, each with 512 × 512 pixels, and a pixel size of approximately 200 nm, were acquired. A spatial averaging filter with a 3 × 3 mask was used to denoise the images. Co-localization analysis was carried out by calculating the PCCs between the pixel intensities of the two detection channels in pixels representing the plasma membrane (<xref ref-type="bibr" rid="bib58">Vámosi et al., 2004</xref>). Only pixels where at least one of the intensities was above the threshold (2× the average autofluorescence intensity) were included in the analysis. Image analysis methods and routines were implemented in MATLAB scripts (Mathworks Inc, Natick, MA) (<xref ref-type="bibr" rid="bib62">Volkó et al., 2019</xref>).</p></sec><sec id="s4-12"><title>Fluorescence correlation spectroscopy</title><p>To distinguish-free and ABCG2-bound MX molecules based on their different diffusion properties, FCS measurements were performed. FCS measurements were carried out using a Nikon A1 Eclipse Ti2 Confocal Laser-Scanning Microscope (Nikon, Tokyo, Japan), equipped with a Plan Apo 60×water objective (NA = 1.27) and a PicoQuant time-correlated single photon counting FCS (TCSPC-FCS) upgrade kit (PicoQuant, Berlin, Germany).</p><p>FCS measurements were carried out on live MDCK cells expressing ABCG2-GFP in eight-well chambered coverslip plates (ibidi GmbH, Gräfelfing, Germany). Cells were stained with 100 nM MX for 15 min at 37°C in the presence or absence of 2 µM Ko143 or after ATP depletion. Fluorescence of ABCG2-GFP and MX was excited with a 488 and a 647 nm laser, respectively. The fluorescence signals emitted by ABCG2-GFP and MX were detected in the spectral ranges of 500–550 and 660–740 nm using single photon counting detectors (PicoQuant, Berlin, Germany). Measurements of 10 × 10 s runs were taken at three selected points in the cross-section of the plasma membrane of each selected cell. Fluorescence autocorrelation curves were calculated using SymPhoTime64 software (PicoQuant, Berlin, Germany) at 200 time points from 300 ns to 1 s with a quasi-logarithmic time scale.</p><p>Autocorrelation curves of the doubly labeled cells were fitted to a triplet state model with two diffusion components to describe the 3D-diffusion of free MX (fast component) and the 2D diffusion of ABCG2-bound MX in the x-z plane of the plasma membrane (slow component). The laser beam was positioned in a region of the cell membrane parallel to the long axis of the ellipsoidal laser volume.<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mi>G</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>τ</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>T</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mo>-</mml:mo><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>i</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>T</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mfenced separators="|"><mml:mrow><mml:mi>ρ</mml:mi><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:mfenced><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msqrt><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>In <xref ref-type="disp-formula" rid="equ3">Equation 3</xref>, N is the average number of fluorescent molecules in the detection volume, T is the fraction of molecules in the triplet state, <italic>τ</italic><sub><italic>trip</italic></sub> is the triplet correlation time. The diffusion rate is characterized by the diffusion time <italic>τ</italic><sub><italic>D</italic></sub>, which is the average time spent by a molecule in the illuminated volume. <italic>τ</italic><sub><italic>D1</italic></sub> and <italic>τ</italic><sub><italic>D2</italic></sub> are the diffusion times of the fast and slow components, <italic>ρ</italic> is the fraction of the first component, and 1−<italic>ρ</italic> is the fraction of the second component. The diffusion coefficients (<italic>D</italic>) of the fast and slow components were determined from the following equation:<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>τ</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Wherein, <italic>ω</italic><sub><italic>xy</italic></sub> is the lateral e<sup>–2</sup> radius of the detection volume. <italic>ω</italic><sub><italic>xy</italic></sub> was measured by determining the diffusion time of 100 nM A647 dye (dissolved in 10 mM Tris, 0.1 mM EDTA-containing buffer, and pH 7.4) with known diffusion coefficient (D<sub>A647</sub> = 330 µm<sup>2</sup>/s, at T = 22.5°C) (<xref ref-type="bibr" rid="bib64">Weidemann and Schwille, 2013</xref>) and substituting it into <xref ref-type="disp-formula" rid="equ4">Equation 4</xref> that corresponds to the aspect ratio of the ellipsoidal confocal volume, defined as the ratio of its axial and radial dimensions. This parameter was estimated by fitting the autocorrelation curves of a 100 nM A647 dye solution.</p></sec><sec id="s4-13"><title>Statistical analysis and curve fitting</title><p>For the statistical analysis of data, SigmaPlot (version 14, SSI, San Jose, CA) was used. For the comparison of two samples from normally distributed populations with equal variances, Student’s t-test was performed, while in case of unequal variances a Kolmogorov-Smirnov test was applied. Multiple comparisons were performed with analysis of variance applying the Holm-Sidak test for post hoc pair-wise comparison of the data. In the case of unequal variances, the Dunnett T3 post hoc pair-wise comparison method was used. Differences were considered significant at p &lt; 0.05.</p><p>All curve fitting was carried out by SigmaPlot (version 14, SSI, San Jose, CA) except for fitting of autocorrelation curves that was performed by using the QuickFit 3.0 software developed in the group B040 (Prof. Jörg Langowski) at the German Cancer Research Center (DKFZ).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Methodology</p></fn><fn fn-type="con" id="con9"><p>Funding acquisition, Methodology</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83976-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated during this study are included in the manuscript. Source Data files have been provided for Table 1, Figure 2 and Figures 4 to 8.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank László Csanády for the critical reading of the manuscript and for helpful discussions, and Adél Vezendiné Nagy for her skilful technical assistance. We are grateful for the financial support by the Hungarian National Research, Development and Innovations Office (NKFIH; <ext-link ext-link-type="uri" xlink:href="https://nkfih.gov.hu/english">https://nkfih.gov.hu/english</ext-link>), grant number K124815 to KG, GINOP-2.2.1-15-2017-00079 to JR and KG, and HunProtEx 2018–1.2.1-NKP-2018–00005 and RRF-2.3.1-21-2022-00015 to GS. GS and TS was also supported by the Austrian Science Fund SFB35.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Shawi</surname><given-names>MK</given-names></name><name><surname>Polar</surname><given-names>MK</given-names></name><name><surname>Omote</surname><given-names>H</given-names></name><name><surname>Figler</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>52629</fpage><lpage>52640</lpage><pub-id pub-id-type="doi">10.1074/jbc.M308175200</pub-id><pub-id pub-id-type="pmid">14551217</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arana</surname><given-names>MR</given-names></name><name><surname>Altenberg</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Atp-Binding cassette exporters: structure and mechanism with a focus on P-glycoprotein and MRP1</article-title><source>Current Medicinal Chemistry</source><volume>26</volume><fpage>1062</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.2174/0929867324666171012105143</pub-id><pub-id pub-id-type="pmid">29022498</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bársony</surname><given-names>O</given-names></name><name><surname>Szalóki</surname><given-names>G</given-names></name><name><surname>Türk</surname><given-names>D</given-names></name><name><surname>Tarapcsák</surname><given-names>S</given-names></name><name><surname>Gutay-Tóth</surname><given-names>Z</given-names></name><name><surname>Bacsó</surname><given-names>Z</given-names></name><name><surname>Holb</surname><given-names>IJ</given-names></name><name><surname>Székvölgyi</surname><given-names>L</given-names></name><name><surname>Szabó</surname><given-names>G</given-names></name><name><surname>Csanády</surname><given-names>L</given-names></name><name><surname>Szakács</surname><given-names>G</given-names></name><name><surname>Goda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A single active catalytic site is sufficient to promote transport in P-glycoprotein</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>24810</elocation-id><pub-id pub-id-type="doi">10.1038/srep24810</pub-id><pub-id pub-id-type="pmid">27117502</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordignon</surname><given-names>E</given-names></name><name><surname>Seeger</surname><given-names>MA</given-names></name><name><surname>Galazzo</surname><given-names>L</given-names></name><name><surname>Meier</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>From in vitro towards in situ: structure-based investigation of ABC exporters by electron paramagnetic resonance spectroscopy</article-title><source>FEBS Letters</source><volume>594</volume><fpage>3839</fpage><lpage>3856</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14004</pub-id><pub-id pub-id-type="pmid">33219535</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catipovic</surname><given-names>MA</given-names></name><name><surname>Bauer</surname><given-names>BW</given-names></name><name><surname>Loparo</surname><given-names>JJ</given-names></name><name><surname>Rapoport</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Protein translocation by the SecA ATPase occurs by a power-stroke mechanism</article-title><source>The EMBO Journal</source><volume>38</volume><elocation-id>e101140</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2018101140</pub-id><pub-id pub-id-type="pmid">30877095</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Abcg2: a potential marker of stem cells and novel target in stem cell and cancer therapy</article-title><source>Life Sciences</source><volume>86</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2010.02.012</pub-id><pub-id pub-id-type="pmid">20159023</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doshi</surname><given-names>R</given-names></name><name><surname>van Veen</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Substrate binding stabilizes a pre-translocation intermediate in the ATP-binding cassette transport protein MsbA</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>21638</fpage><lpage>21647</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.485714</pub-id><pub-id pub-id-type="pmid">23766512</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>LA</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Abruzzo</surname><given-names>LV</given-names></name><name><surname>Krogmann</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Rishi</surname><given-names>AK</given-names></name><name><surname>Ross</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A multidrug resistance transporter from human MCF-7 breast cancer cells</article-title><source>PNAS</source><volume>95</volume><fpage>15665</fpage><lpage>15670</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.26.15665</pub-id><pub-id pub-id-type="pmid">9861027</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdei</surname><given-names>Z</given-names></name><name><surname>Schamberger</surname><given-names>A</given-names></name><name><surname>Török</surname><given-names>G</given-names></name><name><surname>Szebényi</surname><given-names>K</given-names></name><name><surname>Várady</surname><given-names>G</given-names></name><name><surname>Orbán</surname><given-names>TI</given-names></name><name><surname>Homolya</surname><given-names>L</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name><name><surname>Apáti</surname><given-names>Á</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Generation of multidrug resistant human tissues by overexpression of the ABCG2 multidrug transporter in embryonic stem cells</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0194925</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0194925</pub-id><pub-id pub-id-type="pmid">29649238</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fetsch</surname><given-names>PA</given-names></name><name><surname>Abati</surname><given-names>A</given-names></name><name><surname>Litman</surname><given-names>T</given-names></name><name><surname>Morisaki</surname><given-names>K</given-names></name><name><surname>Honjo</surname><given-names>Y</given-names></name><name><surname>Mittal</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues</article-title><source>Cancer Letters</source><volume>235</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.04.024</pub-id><pub-id pub-id-type="pmid">15990223</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>AJ</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Thoden</surname><given-names>JB</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Sutoh</surname><given-names>K</given-names></name><name><surname>Holden</surname><given-names>HM</given-names></name><name><surname>Rayment</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>X-Ray structures of the myosin motor domain of <italic>Dictyostelium</italic> discoideum complexed with MgADP.BeFx and MgADP.AlF4-</article-title><source>Biochemistry</source><volume>34</volume><fpage>8960</fpage><lpage>8972</lpage><pub-id pub-id-type="doi">10.1021/bi00028a004</pub-id><pub-id pub-id-type="pmid">7619795</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futamata</surname><given-names>R</given-names></name><name><surname>Ogasawara</surname><given-names>F</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Kodan</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Kioka</surname><given-names>N</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>In vivo FRET analyses reveal a role of ATP hydrolysis-associated conformational changes in human P-glycoprotein</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>5002</fpage><lpage>5011</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.012042</pub-id><pub-id pub-id-type="pmid">32111736</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacomini</surname><given-names>KM</given-names></name><name><surname>Balimane</surname><given-names>PV</given-names></name><name><surname>Cho</surname><given-names>SK</given-names></name><name><surname>Eadon</surname><given-names>M</given-names></name><name><surname>Edeki</surname><given-names>T</given-names></name><name><surname>Hillgren</surname><given-names>KM</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Weitz</surname><given-names>D</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>CQ</given-names></name><name><surname>Yee</surname><given-names>SW</given-names></name><name><surname>Zimdahl</surname><given-names>H</given-names></name><name><surname>Niemi</surname><given-names>M</given-names></name><collab>International Transporter Consortium</collab></person-group><year iso-8601-date="2013">2013</year><article-title>International transporter Consortium commentary on clinically important transporter polymorphisms</article-title><source>Clinical Pharmacology and Therapeutics</source><volume>94</volume><fpage>23</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1038/clpt.2013.12</pub-id><pub-id pub-id-type="pmid">23778707</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goda</surname><given-names>K</given-names></name><name><surname>Dönmez-Cakil</surname><given-names>Y</given-names></name><name><surname>Tarapcsák</surname><given-names>S</given-names></name><name><surname>Szalóki</surname><given-names>G</given-names></name><name><surname>Szöllősi</surname><given-names>D</given-names></name><name><surname>Parveen</surname><given-names>Z</given-names></name><name><surname>Türk</surname><given-names>D</given-names></name><name><surname>Szakács</surname><given-names>G</given-names></name><name><surname>Chiba</surname><given-names>P</given-names></name><name><surname>Stockner</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human ABCB1 with an ABCB11-like degenerate nucleotide binding site maintains transport activity by avoiding nucleotide occlusion</article-title><source>PLOS Genetics</source><volume>16</volume><elocation-id>e1009016</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1009016</pub-id><pub-id pub-id-type="pmid">33031417</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haider</surname><given-names>AJ</given-names></name><name><surname>Briggs</surname><given-names>D</given-names></name><name><surname>Self</surname><given-names>TJ</given-names></name><name><surname>Chilvers</surname><given-names>HL</given-names></name><name><surname>Holliday</surname><given-names>ND</given-names></name><name><surname>Kerr</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dimerization of ABCG2 analysed by bimolecular fluorescence complementation</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e25818</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025818</pub-id><pub-id pub-id-type="pmid">21991363</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homolya</surname><given-names>L</given-names></name><name><surname>Orbán</surname><given-names>TI</given-names></name><name><surname>Csanády</surname><given-names>L</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mitoxantrone is expelled by the ABCG2 multidrug transporter directly from the plasma membrane</article-title><source>Biochimica et Biophysica Acta</source><volume>1808</volume><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2010.07.031</pub-id><pub-id pub-id-type="pmid">20691148</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homolya</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Medically important alterations in transport function and trafficking of ABCG2</article-title><source>International Journal of Molecular Sciences</source><volume>22</volume><elocation-id>2786</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22062786</pub-id><pub-id pub-id-type="pmid">33801813</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsey</surname><given-names>AJ</given-names></name><name><surname>Briggs</surname><given-names>DA</given-names></name><name><surname>Holliday</surname><given-names>ND</given-names></name><name><surname>Briddon</surname><given-names>SJ</given-names></name><name><surname>Kerr</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Application of fluorescence correlation spectroscopy to study substrate binding in styrene maleic acid lipid copolymer encapsulated abcg2</article-title><source>Biochimica et Biophysica Acta. Biomembranes</source><volume>1862</volume><elocation-id>183218</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbamem.2020.183218</pub-id><pub-id pub-id-type="pmid">32057756</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Aw</surname><given-names>W</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Metabolic interactions of purine derivatives with human ABC transporter ABCG2: genetic testing to assess gout risk</article-title><source>Pharmaceuticals</source><volume>6</volume><fpage>1347</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.3390/ph6111347</pub-id><pub-id pub-id-type="pmid">24287461</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>SM</given-names></name><name><surname>Manolaridis</surname><given-names>I</given-names></name><name><surname>Kowal</surname><given-names>J</given-names></name><name><surname>Zechner</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>NMI</given-names></name><name><surname>Bause</surname><given-names>M</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Bartholomaeus</surname><given-names>R</given-names></name><name><surname>Bernhardt</surname><given-names>G</given-names></name><name><surname>Koenig</surname><given-names>B</given-names></name><name><surname>Buschauer</surname><given-names>A</given-names></name><name><surname>Stahlberg</surname><given-names>H</given-names></name><name><surname>Altmann</surname><given-names>K-H</given-names></name><name><surname>Locher</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>25</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1038/s41594-018-0049-1</pub-id><pub-id pub-id-type="pmid">29610494</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Januliene</surname><given-names>D</given-names></name><name><surname>Moeller</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-Em of ABC transporters: an ice-cold solution to everything?</article-title><source>FEBS Letters</source><volume>594</volume><fpage>3776</fpage><lpage>3789</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.13989</pub-id><pub-id pub-id-type="pmid">33156959</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardetzky</surname><given-names>O</given-names></name></person-group><year iso-8601-date="1966">1966</year><article-title>Simple allosteric model for membrane pumps</article-title><source>Nature</source><volume>211</volume><fpage>969</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1038/211969a0</pub-id><pub-id pub-id-type="pmid">5968307</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonker</surname><given-names>JW</given-names></name><name><surname>Buitelaar</surname><given-names>M</given-names></name><name><surname>Wagenaar</surname><given-names>E</given-names></name><name><surname>Van Der Valk</surname><given-names>MA</given-names></name><name><surname>Scheffer</surname><given-names>GL</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>Plosch</surname><given-names>T</given-names></name><name><surname>Kuipers</surname><given-names>F</given-names></name><name><surname>Elferink</surname><given-names>R</given-names></name><name><surname>Rosing</surname><given-names>H</given-names></name><name><surname>Beijnen</surname><given-names>JH</given-names></name><name><surname>Schinkel</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria</article-title><source>PNAS</source><volume>99</volume><fpage>15649</fpage><lpage>15654</lpage><pub-id pub-id-type="doi">10.1073/pnas.202607599</pub-id><pub-id pub-id-type="pmid">12429862</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josts</surname><given-names>I</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Monteiro</surname><given-names>DCF</given-names></name><name><surname>Niebling</surname><given-names>S</given-names></name><name><surname>Nitsche</surname><given-names>J</given-names></name><name><surname>Veith</surname><given-names>K</given-names></name><name><surname>Gräwert</surname><given-names>TW</given-names></name><name><surname>Blanchet</surname><given-names>CE</given-names></name><name><surname>Schroer</surname><given-names>MA</given-names></name><name><surname>Huse</surname><given-names>N</given-names></name><name><surname>Pearson</surname><given-names>AR</given-names></name><name><surname>Svergun</surname><given-names>DI</given-names></name><name><surname>Tidow</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural kinetics of msba investigated by stopped-flow time-resolved small-angle X-ray scattering</article-title><source>Structure</source><volume>28</volume><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/j.str.2019.12.001</pub-id><pub-id pub-id-type="pmid">31899087</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kage</surname><given-names>K</given-names></name><name><surname>Tsukahara</surname><given-names>S</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Asada</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>E</given-names></name><name><surname>Tsuruo</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Dominant-Negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization</article-title><source>International Journal of Cancer</source><volume>97</volume><fpage>626</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1002/ijc.10100</pub-id><pub-id pub-id-type="pmid">11807788</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>P</given-names></name><name><surname>Horsey</surname><given-names>AJ</given-names></name><name><surname>Cox</surname><given-names>MH</given-names></name><name><surname>Kerr</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Abcg2: does resolving its structure elucidate the mechanism?</article-title><source>Biochemical Society Transactions</source><volume>46</volume><fpage>1485</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1042/BST20180145</pub-id><pub-id pub-id-type="pmid">30464049</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khunweeraphong</surname><given-names>N</given-names></name><name><surname>Stockner</surname><given-names>T</given-names></name><name><surname>Kuchler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>13767</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-11794-w</pub-id><pub-id pub-id-type="pmid">29061978</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khunweeraphong</surname><given-names>N</given-names></name><name><surname>Szöllősi</surname><given-names>D</given-names></name><name><surname>Stockner</surname><given-names>T</given-names></name><name><surname>Kuchler</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5433</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13302-2</pub-id><pub-id pub-id-type="pmid">31780715</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köttgen</surname><given-names>A</given-names></name><name><surname>Köttgen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A novel mouse model of hyperuricemia expressing a human functional ABCG2 variant</article-title><source>Kidney International</source><volume>99</volume><fpage>12</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2020.10.021</pub-id><pub-id pub-id-type="pmid">33390224</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MJ</given-names></name><name><surname>Nath</surname><given-names>A</given-names></name><name><surname>Atkins</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Differential coupling of binding, ATP hydrolysis, and transport of fluorescent probes with P-glycoprotein in lipid nanodiscs</article-title><source>Biochemistry</source><volume>56</volume><fpage>2506</fpage><lpage>2517</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.6b01245</pub-id><pub-id pub-id-type="pmid">28441502</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locher</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Review. structure and mechanism of ATP-binding cassette transporters</article-title><source>Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences</source><volume>364</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1098/rstb.2008.0125</pub-id><pub-id pub-id-type="pmid">18957379</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locher</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanistic diversity in ATP-binding cassette (ABC) transporters</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>23</volume><fpage>487</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3216</pub-id><pub-id pub-id-type="pmid">27273632</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusvarghi</surname><given-names>S</given-names></name><name><surname>Durell</surname><given-names>SR</given-names></name><name><surname>Ambudkar</surname><given-names>SV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Does the ATP-bound EQ mutant reflect the pre- or post-ATP hydrolysis state in the catalytic cycle of human P-glycoprotein (ABCB1)?</article-title><source>FEBS Letters</source><volume>595</volume><fpage>750</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14054</pub-id><pub-id pub-id-type="pmid">33547668</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolaridis</surname><given-names>I</given-names></name><name><surname>Jackson</surname><given-names>SM</given-names></name><name><surname>Taylor</surname><given-names>NMI</given-names></name><name><surname>Kowal</surname><given-names>J</given-names></name><name><surname>Stahlberg</surname><given-names>H</given-names></name><name><surname>Locher</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cryo-Em structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states</article-title><source>Nature</source><volume>563</volume><fpage>426</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0680-3</pub-id><pub-id pub-id-type="pmid">30405239</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcoux</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Politis</surname><given-names>A</given-names></name><name><surname>Reading</surname><given-names>E</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Biggin</surname><given-names>PC</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Morgner</surname><given-names>N</given-names></name><name><surname>Robinson</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump</article-title><source>PNAS</source><volume>110</volume><fpage>9704</fpage><lpage>9709</lpage><pub-id pub-id-type="doi">10.1073/pnas.1303888110</pub-id><pub-id pub-id-type="pmid">23690617</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Higgins</surname><given-names>CF</given-names></name><name><surname>Callaghan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein</article-title><source>Biochemistry</source><volume>40</volume><fpage>15733</fpage><lpage>15742</lpage><pub-id pub-id-type="doi">10.1021/bi011211z</pub-id><pub-id pub-id-type="pmid">11747450</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDevitt</surname><given-names>CA</given-names></name><name><surname>Crowley</surname><given-names>E</given-names></name><name><surname>Hobbs</surname><given-names>G</given-names></name><name><surname>Starr</surname><given-names>KJ</given-names></name><name><surname>Kerr</surname><given-names>ID</given-names></name><name><surname>Callaghan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2?</article-title><source>The FEBS Journal</source><volume>275</volume><fpage>4354</fpage><lpage>4362</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2008.06578.x</pub-id><pub-id pub-id-type="pmid">18657189</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Tao</surname><given-names>H</given-names></name><name><surname>Speir</surname><given-names>JA</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Urbatsch</surname><given-names>IL</given-names></name><name><surname>Potter</surname><given-names>CS</given-names></name><name><surname>Carragher</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Distinct conformational spectrum of homologous multidrug ABC transporters</article-title><source>Structure</source><volume>23</volume><fpage>450</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.str.2014.12.013</pub-id><pub-id pub-id-type="pmid">25661651</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orbán</surname><given-names>TI</given-names></name><name><surname>Seres</surname><given-names>L</given-names></name><name><surname>Ozvegy-Laczka</surname><given-names>C</given-names></name><name><surname>Elkind</surname><given-names>NB</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name><name><surname>Homolya</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter</article-title><source>Biochemical and Biophysical Research Communications</source><volume>367</volume><fpage>667</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2007.12.172</pub-id><pub-id pub-id-type="pmid">18182157</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orelle</surname><given-names>C</given-names></name><name><surname>Schmitt</surname><given-names>L</given-names></name><name><surname>Jault</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Waste or die: the price to pay to stay alive</article-title><source>Trends in Microbiology</source><elocation-id>S0966-842X(22)00250-5</elocation-id><pub-id pub-id-type="doi">10.1016/j.tim.2022.09.005</pub-id><pub-id pub-id-type="pmid">36192292</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlando</surname><given-names>BJ</given-names></name><name><surname>Liao</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Abcg2 transports anticancer drugs via a closed-to-open switch</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2264</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16155-2</pub-id><pub-id pub-id-type="pmid">32385283</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozvegy</surname><given-names>C</given-names></name><name><surname>Litman</surname><given-names>T</given-names></name><name><surname>Szakács</surname><given-names>G</given-names></name><name><surname>Nagy</surname><given-names>Z</given-names></name><name><surname>Bates</surname><given-names>S</given-names></name><name><surname>Váradi</surname><given-names>A</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>285</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.5130</pub-id><pub-id pub-id-type="pmid">11437380</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozvegy-Laczka</surname><given-names>C</given-names></name><name><surname>Várady</surname><given-names>G</given-names></name><name><surname>Köblös</surname><given-names>G</given-names></name><name><surname>Ujhelly</surname><given-names>O</given-names></name><name><surname>Cervenak</surname><given-names>J</given-names></name><name><surname>Schuetz</surname><given-names>JD</given-names></name><name><surname>Sorrentino</surname><given-names>BP</given-names></name><name><surname>Koomen</surname><given-names>G-J</given-names></name><name><surname>Váradi</surname><given-names>A</given-names></name><name><surname>Német</surname><given-names>K</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>4219</fpage><lpage>4227</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411338200</pub-id><pub-id pub-id-type="pmid">15557326</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pál</surname><given-names>A</given-names></name><name><surname>Méhn</surname><given-names>D</given-names></name><name><surname>Molnár</surname><given-names>E</given-names></name><name><surname>Gedey</surname><given-names>S</given-names></name><name><surname>Mészáros</surname><given-names>P</given-names></name><name><surname>Nagy</surname><given-names>T</given-names></name><name><surname>Glavinas</surname><given-names>H</given-names></name><name><surname>Janáky</surname><given-names>T</given-names></name><name><surname>von Richter</surname><given-names>O</given-names></name><name><surname>Báthori</surname><given-names>G</given-names></name><name><surname>Szente</surname><given-names>L</given-names></name><name><surname>Krajcsi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>321</volume><fpage>1085</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.119289</pub-id><pub-id pub-id-type="pmid">17347325</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romsicki</surname><given-names>Y</given-names></name><name><surname>Sharom</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The ATPase and ATP-binding functions of P-glycoprotein -- modulation by interaction with defined phospholipids</article-title><source>European Journal of Biochemistry</source><volume>256</volume><fpage>170</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.1998.2560170.x</pub-id><pub-id pub-id-type="pmid">9746361</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothnie</surname><given-names>A</given-names></name><name><surname>Callaghan</surname><given-names>R</given-names></name><name><surname>Deeley</surname><given-names>RG</given-names></name><name><surname>Cole</surname><given-names>SPC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1)</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>13906</fpage><lpage>13914</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600869200</pub-id><pub-id pub-id-type="pmid">16565074</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkadi</surname><given-names>B</given-names></name><name><surname>Price</surname><given-names>EM</given-names></name><name><surname>Boucher</surname><given-names>RC</given-names></name><name><surname>Germann</surname><given-names>UA</given-names></name><name><surname>Scarborough</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase</article-title><source>The Journal of Biological Chemistry</source><volume>267</volume><fpage>4854</fpage><lpage>4858</lpage><pub-id pub-id-type="pmid">1347044</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkadi</surname><given-names>B</given-names></name><name><surname>Homolya</surname><given-names>L</given-names></name><name><surname>Szakács</surname><given-names>G</given-names></name><name><surname>Váradi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system</article-title><source>Physiological Reviews</source><volume>86</volume><fpage>1179</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1152/physrev.00037.2005</pub-id><pub-id pub-id-type="pmid">17015488</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeger</surname><given-names>MA</given-names></name><name><surname>van Veen</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Molecular basis of multidrug transport by ABC transporters</article-title><source>Biochimica et Biophysica Acta</source><volume>1794</volume><fpage>725</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2008.12.004</pub-id><pub-id pub-id-type="pmid">19135557</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Rayment</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>X-ray structure of the magnesium(II).ADP.vanadate complex of the dictyostelium discoideum myosin motor domain to 1.9 A resolution</article-title><source>Biochemistry</source><volume>35</volume><fpage>5404</fpage><lpage>5417</lpage><pub-id pub-id-type="doi">10.1021/bi952633+</pub-id><pub-id pub-id-type="pmid">8611530</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockner</surname><given-names>T</given-names></name><name><surname>Gradisch</surname><given-names>R</given-names></name><name><surname>Schmitt</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The role of the degenerate nucleotide binding site in type I ABC exporters</article-title><source>FEBS Letters</source><volume>594</volume><fpage>3815</fpage><lpage>3838</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.13997</pub-id><pub-id pub-id-type="pmid">33179257</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Sugimoto</surname><given-names>Y</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Abcg2 transports sulfated conjugates of steroids and xenobiotics</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>22644</fpage><lpage>22649</lpage><pub-id pub-id-type="doi">10.1074/jbc.M212399200</pub-id><pub-id pub-id-type="pmid">12682043</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabó</surname><given-names>K</given-names></name><name><surname>Welker</surname><given-names>E</given-names></name><name><surname>Bakos</surname><given-names>É</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Roninson</surname><given-names>I</given-names></name><name><surname>Váradi</surname><given-names>A</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Drug-Stimulated nucleotide trapping in the human multidrug transporter MDR1</article-title><source>Journal of Biological Chemistry</source><volume>273</volume><fpage>10132</fpage><lpage>10138</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.17.10132</pub-id><pub-id pub-id-type="pmid">9553060</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szakács</surname><given-names>G</given-names></name><name><surname>Ozvegy</surname><given-names>C</given-names></name><name><surname>Bakos</surname><given-names>E</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name><name><surname>Váradi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Transition-State formation in ATPase-negative mutants of human MDR1 protein</article-title><source>Biochemical and Biophysical Research Communications</source><volume>276</volume><fpage>1314</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.3576</pub-id><pub-id pub-id-type="pmid">11027628</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarapcsák</surname><given-names>S</given-names></name><name><surname>Szalóki</surname><given-names>G</given-names></name><name><surname>Telbisz</surname><given-names>Á</given-names></name><name><surname>Gyöngy</surname><given-names>Z</given-names></name><name><surname>Matúz</surname><given-names>K</given-names></name><name><surname>Csősz</surname><given-names>É</given-names></name><name><surname>Nagy</surname><given-names>P</given-names></name><name><surname>Holb</surname><given-names>IJ</given-names></name><name><surname>Rühl</surname><given-names>R</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Szabó</surname><given-names>G</given-names></name><name><surname>Goda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interactions of retinoids with the ABC transporters P-glycoprotein and breast cancer resistance protein</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>41376</elocation-id><pub-id pub-id-type="doi">10.1038/srep41376</pub-id><pub-id pub-id-type="pmid">28145501</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>NMI</given-names></name><name><surname>Manolaridis</surname><given-names>I</given-names></name><name><surname>Jackson</surname><given-names>SM</given-names></name><name><surname>Kowal</surname><given-names>J</given-names></name><name><surname>Stahlberg</surname><given-names>H</given-names></name><name><surname>Locher</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure of the human multidrug transporter ABCG2</article-title><source>Nature</source><volume>546</volume><fpage>504</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/nature22345</pub-id><pub-id pub-id-type="pmid">28554189</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telbisz</surname><given-names>Á</given-names></name><name><surname>Hegedüs</surname><given-names>C</given-names></name><name><surname>Özvegy-Laczka</surname><given-names>C</given-names></name><name><surname>Goda</surname><given-names>K</given-names></name><name><surname>Várady</surname><given-names>G</given-names></name><name><surname>Takáts</surname><given-names>Z</given-names></name><name><surname>Szabó</surname><given-names>E</given-names></name><name><surname>Sorrentino</surname><given-names>BP</given-names></name><name><surname>Váradi</surname><given-names>A</given-names></name><name><surname>Sarkadi</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter</article-title><source>European Journal of Pharmaceutical Sciences</source><volume>45</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2011.10.021</pub-id><pub-id pub-id-type="pmid">22115866</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vámosi</surname><given-names>G</given-names></name><name><surname>Bodnár</surname><given-names>A</given-names></name><name><surname>Vereb</surname><given-names>G</given-names></name><name><surname>Jenei</surname><given-names>A</given-names></name><name><surname>Goldman</surname><given-names>CK</given-names></name><name><surname>Langowski</surname><given-names>J</given-names></name><name><surname>Tóth</surname><given-names>K</given-names></name><name><surname>Mátyus</surname><given-names>L</given-names></name><name><surname>Szöllösi</surname><given-names>J</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Damjanovich</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells</article-title><source>PNAS</source><volume>101</volume><fpage>11082</fpage><lpage>11087</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403916101</pub-id><pub-id pub-id-type="pmid">15263076</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Herwaarden</surname><given-names>AE</given-names></name><name><surname>Schinkel</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins</article-title><source>Trends in Pharmacological Sciences</source><volume>27</volume><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2005.11.007</pub-id><pub-id pub-id-type="pmid">16337280</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Wonderen</surname><given-names>JH</given-names></name><name><surname>McMahon</surname><given-names>RM</given-names></name><name><surname>O’Mara</surname><given-names>ML</given-names></name><name><surname>McDevitt</surname><given-names>CA</given-names></name><name><surname>Thomson</surname><given-names>AJ</given-names></name><name><surname>Kerr</surname><given-names>ID</given-names></name><name><surname>MacMillan</surname><given-names>F</given-names></name><name><surname>Callaghan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The central cavity of ABCB1 undergoes alternating access during ATP hydrolysis</article-title><source>The FEBS Journal</source><volume>281</volume><fpage>2190</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1111/febs.12773</pub-id><pub-id pub-id-type="pmid">24597976</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vergani</surname><given-names>P</given-names></name><name><surname>Gadsby</surname><given-names>DC</given-names></name><name><surname>Csanady</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><chapter-title>CFTR, an ion channel evolved from ABC transporter</chapter-title><person-group person-group-type="editor"><name><surname>Roberts</surname><given-names>GCK</given-names></name></person-group><source>Encyclopedia of Biophysics</source><publisher-loc>Berlin, Heidelberg</publisher-loc><publisher-name>Springer Berlin Heidelberg</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-642-16712-6_364</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkó</surname><given-names>J</given-names></name><name><surname>Kenesei</surname><given-names>Á</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Várnai</surname><given-names>P</given-names></name><name><surname>Mocsár</surname><given-names>G</given-names></name><name><surname>Petrus</surname><given-names>MN</given-names></name><name><surname>Jambrovics</surname><given-names>K</given-names></name><name><surname>Balajthy</surname><given-names>Z</given-names></name><name><surname>Müller</surname><given-names>G</given-names></name><name><surname>Bodnár</surname><given-names>A</given-names></name><name><surname>Tóth</surname><given-names>K</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Vámosi</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>IL-2 receptors preassemble and signal in the ER/golgi causing resistance to antiproliferative anti–IL-2rα therapies</article-title><source>PNAS</source><volume>116</volume><fpage>21120</fpage><lpage>21130</lpage><pub-id pub-id-type="doi">10.1073/pnas.1901382116</pub-id><pub-id pub-id-type="pmid">31152927</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>ZL</given-names></name><name><surname>Wasserman</surname><given-names>MR</given-names></name><name><surname>Levring</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characterization of the kinetic cycle of an ABC transporter by single-molecule and cryo-EM analyses</article-title><source>eLife</source><volume>9</volume><elocation-id>e56451</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.56451</pub-id><pub-id pub-id-type="pmid">32458799</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidemann</surname><given-names>T</given-names></name><name><surname>Schwille</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dual-color fluorescence cross-correlation spectroscopy with continuous laser excitation in a confocal setup</article-title><source>Methods in Enzymology</source><volume>518</volume><fpage>43</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-388422-0.00003-0</pub-id><pub-id pub-id-type="pmid">23276535</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>SP</given-names></name><name><surname>Fulton</surname><given-names>AM</given-names></name><name><surname>Brindle</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Estimation of the intracellular free ADP concentration by fluorine-19 NMR studies of fluorine-labeled yeast phosphoglycerate kinase in vivo</article-title><source>Biochemistry</source><volume>32</volume><fpage>4895</fpage><lpage>4902</lpage><pub-id pub-id-type="doi">10.1021/bi00069a026</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodward</surname><given-names>OM</given-names></name><name><surname>Köttgen</surname><given-names>A</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Guggino</surname><given-names>WB</given-names></name><name><surname>Köttgen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout</article-title><source>PNAS</source><volume>106</volume><fpage>10338</fpage><lpage>10342</lpage><pub-id pub-id-type="doi">10.1073/pnas.0901249106</pub-id><pub-id pub-id-type="pmid">19506252</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WS</given-names></name><name><surname>Park</surname><given-names>S-O</given-names></name><name><surname>Yoon</surname><given-names>A-R</given-names></name><name><surname>Yoo</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Yun</surname><given-names>C-O</given-names></name><name><surname>Kim</surname><given-names>C-W</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Suicide cancer gene therapy using pore-forming toxin, streptolysin O</article-title><source>Molecular Cancer Therapeutics</source><volume>5</volume><fpage>1610</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-05-0515</pub-id><pub-id pub-id-type="pmid">16818521</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Ni</surname><given-names>D</given-names></name><name><surname>Kowal</surname><given-names>J</given-names></name><name><surname>Manolaridis</surname><given-names>I</given-names></name><name><surname>Jackson</surname><given-names>SM</given-names></name><name><surname>Stahlberg</surname><given-names>H</given-names></name><name><surname>Locher</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>4376</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24651-2</pub-id><pub-id pub-id-type="pmid">34282134</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83976.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Drew</surname><given-names>David</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.19.512890" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.19.512890"/></front-stub><body><p>The ABC transporter ABCG2 extrudes chemotherapy reagents and other xenobiotics from a number of different tissues. How ABCG2 operates at the molecular level has been largely derived from structures and dynamics carried out in non-physiological environments. The paper presents convincing cell-based evidence describing the relationship between structural changes of ABCG2 and substrate binding using flow cytometry, confocal microscopy, and fluorescence-correlation spectroscopy methods. Both the mechanistic conclusions and methodology employed offer important insights, which will be of general interest to the biochemistry and transport biology communities.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83976.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Drew</surname><given-names>David</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05f0yaq80</institution-id><institution>Stockholm University</institution></institution-wrap><country>Sweden</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Lee</surname><given-names>Jyh-Yeuan</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03c4mmv16</institution-id><institution>University of Ottawa</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Jault</surname><given-names>Jean-Michel</given-names></name><role>Reviewer</role><aff><institution>Institut de Biolog UMR5086 CNRS/Université de Lyon</institution><country>France</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.19.512890">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.10.19.512890v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Nucleotide binding is the critical regulator of ABCG2 conformational transitions&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including David Drew as the Reviewng Editor and Reviewer #1, and the evaluation has been overseen by Volker Dötsch as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Jyh-Yeuan Lee (Reviewer #2); Jean-Michel Jault (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) We think it would be appropriate in the discussion to:</p><p>i. put this study in context with other approaches used to assess a synergetic effect of drugs and ATP to reach the OF state for P-gp (Futamata et al., 2020, J. Biol. Chem; Marcoux et al., 2013, PNAS).</p><p>ii. Clarify the limitations of the study, in particular, that the approach only has a read-out for the inward-facing state, half-life of antibody complex, and its inability to directly assess intermediate states and allosteric coupling between the NBDs and TMD regions.</p><p>2) Figure 1: It is unclear why in the presence of ABCG2 ({plus minus}GFP), the addition of Ko143 induces more fluorescence intensity. It looks like there is more 5D3 binding in the presence of Ko, like if this inhibitor could displace the equilibrium towards the IF state of ABCG2. Do you have other antibodies towards ABCG2 that will recognize it regardless of its conformation? Is the presence of other inhibitors or drugs would produce the same effect? How do the authors explain this result?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Overall, I found the paper was technically sound and integrated well with previous structural and biochemical analyses.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>I commend your achievement in this study, especially the solid kinetic data. Thank you for the effort. The following are a few suggestions that I believe would make a stronger argument for your conclusion.</p><p>1. It is not clear to me that the data shows interdomain interaction beyond saying a global switch of IF and OF conformers. There have been a number of mutational studies done at the NBD-TMD interface, either canonical catalytic or disease mutations. By any chance, have the authors looked at the impact of those mutants?</p><p>2. Have you tried to swap the 5D3 epitope on ABCG2 with Pgp's UIC epitope, and you still reached the same conclusion?</p><p>3. This is a minor suggestion to improve Figure 5. The colocalization images are not clear to me on my PDF copy; thus, it would help to reformat the images to better present colocalization.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Line 96: when the authors speak about cavities 1 and 2, it would be useful to show them on the 3D structures of ABCG2. I think they could combine that with Figure 8 which would become the new figure 1 with different panels, some for the cavities and others for the 5D3 epitopes.</p><p>Figure 1: It is unclear why in the presence of ABCG2 ({plus minus}GFP), the addition of Ko143 induces more fluorescence intensity. It looks like there is more 5D3 binding in the presence of Ko, like if this inhibitor could displace the equilibrium towards the IF state of ABCG2. Do you have other antibodies towards ABCG2 that will recognize it regardless of its conformation? Is the presence of other inhibitors or drugs would produce the same effect? How do the authors explain this result?</p><p>Line 183. It is not so unexpected since, in the case of MsbA, APD/Mg/Vi was capable to switch a large proportion of transporter to the OF conformation (Moeller et al., 2015, Structure). This paper should be mentioned in the discussion.</p><p>Lines 216/217. 'Transported substrates increase the turnover rate of ATP hydrolysis in ABC</p><p>transporters'. In fact, it is found in many ABC transporters including eukaryotic multidrug transporter but this is not a general property of all ABC transporters.</p><p>Lines 277/278. '…probably by reducing the energy barrier of the above conformational changes'. You could mention here that this has been proposed for other multidrug ABC transporters when the basal ATPase is strongly stimulated by drugs (Orelle et al., 2022, Trends Microbiol).</p><p>Overall, the discussion part could be developed a little bit more and include two major publications that showed using different techniques a synergetic effect of drugs and ATP to reach the OF state for P-gp (Futamata et al., 2020, J. Biol. Chem; Marcoux et al., 2013, PNAS).</p><p>Lines 463/464, 'ABCG2 can transition from the IF to OF state, and this transition is not</p><p>the rate-limiting step of the whole catalytic cycle'. I don't think that this statement can be made from the data obtained. Clearly, the drugs seem to promote the transition from IF to OF, so affect the energetic barrier for this transition, yet this does not inform us of the rate-limiting step of the transport cycle. I suggest that the authors remove the last part of the sentence.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83976.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) We think it would be appropriate in the discussion to:</p><p>i. put this study in context with other approaches used to assess a synergetic effect of drugs and ATP to reach the OF state for P-gp (Futamata et al., 2020, J. Biol. Chem; Marcoux et al., 2013, PNAS).</p></disp-quote><p>Futamata et al. analyzed nucleotide-induced conformational changes of ABCB1 using FRET. In agreement with the data presented in our manuscript, they find that ATP binding causes conformational changes leading to the outward-facing state, whereas the transported substrate verapamil does not induce a measurable FRET signal without the presence of MgATP. Marcoux et al. use an original approach to probe ABCB1 in a detergent micelle. Based on ion mobility MS analysis, the authors show that ABCB1 exists in an equilibrium between different states, readily interconverted by ligand binding. Both papers are now mentioned, to offer a broader context of our findings (please see lines 466-469 and 438439 in the amended manuscript).</p><disp-quote content-type="editor-comment"><p>ii. Clarify the limitations of the study, in particular, that the approach only has a read-out for the inward-facing state, half-life of antibody complex, and its inability to directly assess intermediate states and allosteric coupling between the NBDs and TMD regions.</p></disp-quote><p>We agree with the Reviewers that the antibody-shift assay has limitations, which should be clearly discussed, and therefore, we included a new paragraph in the Discussion (please see lines 402-409 in the revised manuscript).</p><p>We would like to make two comments here.</p><p>First, we believe that the half-life of the antibody complex does not limit our conclusions.</p><p>Second, the apparent ATP affinity determined in 5D3 reactivity assays (<italic>K</italic><sub>A</sub>) (Figure 3 and Table 1) should be identical to the <italic>K</italic><sub>M</sub> of ATP for ATP-hydrolysis observed at the same (fixed) 5D3 concentration. Since 5D3 stabilizes the IF conformation of ABCG2, it should act as a mixed type inhibitor of ABCG2-mediated ATP-hydrolysis and substrate transport, by lowering the apparent <italic>V<sub>max</sub></italic> and by increasing the apparent <italic>K<sub>M</sub></italic> for ATP. Therefore, the absolute <italic>K<sub>A</sub></italic> values were not used in our reasoning, only differences and changes were interpreted.</p><disp-quote content-type="editor-comment"><p>2) Figure 1: It is unclear why in the presence of ABCG2 ({plus minus}GFP), the addition of Ko143 induces more fluorescence intensity. It looks like there is more 5D3 binding in the presence of Ko, like if this inhibitor could displace the equilibrium towards the IF state of ABCG2.</p></disp-quote><p>Several inhibitors of ABCG2 enhance 5D3 mAb binding probably by shifting the equilibrium to the IF state of the transporter (<italic>J Biol Chem,</italic> 280, 421927.10.1074/jbc.M411338200; Eur J Pharm Sci (2012)45:101-109). Similar phenomenon has been described for UIC2 binding to ABCB1 earlier (e.g., Mechetner, E. B. et al. Proceedings of the National Academy of Sciences of the United States of America 94, 12908-12913 (1997); Goda, K. et al. The Journal of Pharmacology and Experimental Therapeutics 320, 81-88, doi:10.1124/jpet.106.110155 (2007)).</p><p>Note that Ko143 treatment does not affect the ABCG2-GFP fluorescence in the plasma membrane (Figure 5C), indicating that the Ko143-induced shift can be explained by a shift in the equilibrium towards the 5D3-reactive IF conformer, thereby increasing the number of transporters available for 5D3 binding. This is now explained in the text (please see lines 157-162).</p><disp-quote content-type="editor-comment"><p>Do you have other antibodies towards ABCG2 that will recognize it regardless of its conformation?</p></disp-quote><p>Intriguingly, (according to our knowledge) such an antibody (conformation-insensitive, recognizing an extracellular ABCG2 epitope) does not exist.</p><disp-quote content-type="editor-comment"><p>Is the presence of other inhibitors or drugs would produce the same effect? How do the authors explain this result?</p></disp-quote><p>As stated above, several compounds interacting with ABCG2 (inhibitors or substrates added at high (inhibitory) concentrations) result in an increase of 5D3-reactivity (see e.g., Telbisz et al. Eur J Pharm Sci (2012)45:101-109). A similar phenomenon was studied in great detail with ABCB1, based on the drug-induced shift of UIC2 binding (Mechetner, E. B. et al. Proceedings of the National Academy of Sciences of the United States of America <bold>94</bold>, 12908-12913 (1997); Goda, K. et al. The Journal of pharmacology and experimental therapeutics <bold>320</bold>, 81-88, doi:10.1124/jpet.106.110155 (2007).)</p><p>As also demonstrated in the case of ABCB1 (Mechetner, E. B. et al. Proceedings of the National Academy of Sciences of the United States of America <bold>94</bold>, 12908-12913 (1997); Goda, K. et al. The Journal of Pharmacology and Experimental Therapeutics <bold>320</bold>, 81-88, doi:10.1124/jpet.106.110155 (2007)), the likely explanation is that such compounds stabilize the 5D3-reactive (or UIC2-reactive) IF conformer by hindering the transition of the transporters to the OF state.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>I commend your achievement in this study, especially the solid kinetic data. Thank you for the effort. The following are a few suggestions that I believe would make a stronger argument for your conclusion.</p><p>1. It is not clear to me that the data shows interdomain interaction beyond saying a global switch of IF and OF conformers. There have been a number of mutational studies done at the NBD-TMD interface, either canonical catalytic or disease mutations. By any chance, have the authors looked at the impact of those mutants?</p></disp-quote><p>We agree that our data reflect a global switch between IF and OF conformers. In the current work we have not studied the impact of mutations introduced into the NBD-TMD interface on the conformation changes of the protein.</p><disp-quote content-type="editor-comment"><p>2. Have you tried to swap the 5D3 epitope on ABCG2 with Pgp's UIC epitope, and you still reached the same conclusion?</p></disp-quote><p>Very interesting thought, but in our humble opinion, this would be more than a difficult task and most likely cannot be achieved. Both epitopes are composite epitopes that are transiently formed during the catalytic cycle of the transporters. The UIC2 epitope is formed by the 1<sup>st</sup>, 3<sup>rd</sup> and 4<sup>th</sup> extracellular loops of the human ABCB1 (Zhou, Y. at al. (1999). <italic>Archives of Biochemistry and Biophysics</italic> <bold>367</bold>, 74-80 Vahedi, S. et al. 2018. <italic>Scientific Reports</italic> <bold>8</bold>, 12716; Alam, A. et al. (2019) <italic>Science</italic> <bold>363</bold>, 753-756), while the 5D3 epitope is formed mainly by the 3<sup>rd</sup> extracellular loop connecting TM5c and TM6a in the ABCG2 protomers (Taylor NMI et al. <italic>Nature,</italic> 546<bold>,</bold> 504-509.10.1038/nature22345). The ABCG2 dimer collectively forms two epitopes for 5D3 Fab binding. In contrast, only one UIC2 Fab can bind to ABCB1.</p><p>Even in case the amino acids in these loops could in some way be switched between the transporters, this would not lead to the transfer of the epitopes between transporters, because the folds of the extracellular loops are very different, as are the folds of the transmembrane helices.</p><disp-quote content-type="editor-comment"><p>3. This is a minor suggestion to improve Figure 5. The colocalization images are not clear to me on my PDF copy; thus, it would help to reformat the images to better present colocalization.</p></disp-quote><p>We replaced the images with high-quality and high-resolution tif files.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Line 96: when the authors speak about cavities 1 and 2, it would be useful to show them on the 3D structures of ABCG2. I think they could combine that with Figure 8 which would become the new figure 1 with different panels, some for the cavities and others for the 5D3 epitopes.</p></disp-quote><p>We added two panels to Figure 8 showing the cavities in the IF and OF conformations (and relocated this Figure into the Introduction part as a new Figure 1.)</p><disp-quote content-type="editor-comment"><p>Line 183. It is not so unexpected since, in the case of MsbA, APD/Mg/Vi was capable to switch a large proportion of transporter to the OF conformation (Moeller et al., 2015, Structure). This paper should be mentioned in the discussion.</p></disp-quote><p>We agree – thank you for the suggestion (please see lines 197-199 in the revised manuscript).</p><disp-quote content-type="editor-comment"><p>Lines 216/217. 'Transported substrates increase the turnover rate of ATP hydrolysis in ABC transporters'. In fact, it is found in many ABC transporters including eukaryotic multidrug transporter but this is not a general property of all ABC transporters.</p></disp-quote><p>We have modified this sentence according to the Reviewers’ suggestion (please see lines 231/232).</p><disp-quote content-type="editor-comment"><p>Lines 277/278. '…probably by reducing the energy barrier of the above conformational changes'. You could mention here that this has been proposed for other multidrug ABC transporters when the basal ATPase is strongly stimulated by drugs (Orelle et al., 2022, Trends Microbiol).</p></disp-quote><p>Thank you for this suggestion, we have inserted the reference (please see lines 292/293).</p><disp-quote content-type="editor-comment"><p>Lines 463/464, 'ABCG2 can transition from the IF to OF state, and this transition is not the rate-limiting step of the whole catalytic cycle'. I don't think that this statement can be made from the data obtained. Clearly, the drugs seem to promote the transition from IF to OF, so affect the energetic barrier for this transition, yet this does not inform us of the rate-limiting step of the transport cycle. I suggest that the authors remove the last part of the sentence.</p></disp-quote><p>Thank you for this comment. We have reformulated the corresponding section to clarify our reasoning (please see lines 474-508).</p></body></sub-article></article>